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Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2008 
 
Major Director:  Dr. Yan Zhang, Assistant Professor 
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 There are currently many opioid agonists available for clinical use as analgesics. 
However, many of these opioid agonists have notorious side effects including respiratory 
depression and may lead to addiction and dependence.  Problems associated with these 
opioid agonists are determined to come from their interactions with the mu-opioid 
receptor.  Opioid antagonists, such as naltrexone, have shown to aid in the treatment of 
opioid addiction.  Although naltrexone has high affinity to the mu-opioid receptor, it 
lacks selectivity.  Novel selective mu-opioid receptor antagonists were designed based on 
the identification of important pharmacophore elements in several known mu-opioid 
receptor agonists and antagonists.  These compounds were synthesized and in vitro 
biological assays were conducted to determine their affinity to 
xviii 
xix 
all three opioid receptors.  Also, molecular modeling studines were conducted to help 
visualize the interactions between the mu-opioid receptor and these ligands.  Finally, four 
lead compounds have been identified for further optimization.
 
 I. Introduction 
 
Ancient civilizations have used extracts from the poppy flower for analgesic 
purposes.  Around 300 B.C. Theophrastus described the analgesic use of opium in the 
“Inquiry of Plants”.  Opium was a crude extract from the unripe seedpod of the poppy 
flower, Papaver Somniferum.  Morphine is the main active ingredient of opium and was 
isolated by Serturner in 1803.  Later, other morphine-like alkaloids, such as thebaine and 
codeine, were isolated from the same resource.  Morphine is still the most commonly 
used opioid analgesic in clinical settings.1
Morphine produces many effects including analgesia, which makes it useful to 
treat post-operation and chronic pain.  However, morphine also has adverse side effects 
such as respiratory depression, pancreatitis, renal failure, chemical toxicity for patients 
with low tolerability, and raised intracranial pressure that can lead to head injuries.  Most 
significantly, morphine is highly addictive both physically and psychologically.2
Opioids have been associated with abuse and addiction problems for a long time.  
However, it has become more prominent over the last couple of centuries, especially 
since the introduction of the hypodermic needle in the 1950s.  Long-term use of opioids 
may lead to addiction that can result in a compulsive need for opioids.  According to the 
National Survey on Drug Use and Health (NSDUH), in 2005 about 2.2 million people 
1 
2 
used prescription analgesics for non-medical purposes for the first time.3 As of 2007, it is 
estimated about 16 million people worldwide abuse opioids.4  Opioid dependency and 
addiction can be treated through detoxification or drug replacement therapy.   
Morphine, as well as other opioids, mainly acts on the opioid receptors in the 
central nervous system.  There are three major opioid receptors including mu, kappa and 
delta.  All three opioid receptors are involved in analgesia.  However, it has been shown 
that the analgesic effect and adverse side effects of morphine are primarily due to its 
interaction with the mu-opioid receptor.  For example, it was found that the analgesic and 
addictive properties of morphine is abolished in mu-opioid receptor knock-out mice.5  
Therefore, the characterization of the mu-opioid receptor is essential for understanding of 
morphine’s analgesic mechanism and addictive potential. 
Opioid antagonists have played important roles in the pharmacological studies of 
opioid receptors.  Receptor selective antagonists are preferred in characterizing each type 
of opioid receptors.  Due to the role of the mu-opioid receptor in analgesia and drug 
addiction, highly selective mu-opioid receptor antagonists are very useful 
pharmacological tools in the study of the mu-opioid receptor structure-activity 
relationship. 
Naltrexone, a non-peptide opioid antagonist, is a long-acting and reversible opioid 
ligand used for the management of alcohol and opioid dependence.  Naltrexone can also 
be used to treat other types of addiction including compulsive shopping and gambling.  It 
has been shown to promote abstinence and prevent relapse.6  However, naltrexone may 
also carry some side effects including dysphoria, depression, pulmonary edema and 
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cardiac arrhythmias.7,8  These side effects may be related to the low selectivity of 
naltrexone to the opioid receptors.9  On the other hand, there are a couple of selective 
peptidyl mu-opioid receptor antagonists available, including CTOP and CTAP.  
However, these two compounds are peptides and may undergo metabolic inactivation.10  
Therefore, the development of highly selective non-peptide mu-opioid receptor 
antagonists is needed to help alleviate any adverse effects seen by opioid antagonists with 
low selectivity.      
The ability for these ligands to be reversible is also very important in the design 
of opioid antagonists.  Reversible opioid antagonists will temporarily block the opioid 
receptor and can be easily washed out of the binding locus during pharmacological 
studies.  However, irreversible antagonists will covalently bind to the receptor and will 
inactivate the receptor indefinitely.  Therefore, in certain cases reversible mu-opioid 
receptor antagonists are preferred in order to study the mu-opioid receptor. 
Although naltrexone has some problems associated with its low selectivity to the 
opioid receptors, it may be an ideal template for the design of selective mu-opioid 
receptor antagonists.  Naltrexone has subnanomolar to nanomolar affinity to the three 
opioid receptors and shows mild selectivity for the mu- and kappa-opioid receptors over 
the delta-opioid receptor.  It may be helpful to maintain the high affinity for the mu-
opioid receptor by utilizing naltrexone as the backbone in the design of new mu-opioid 
receptor antagonists. 
Previous site-directed mutagenesis and molecular modeling studies have shown 
that certain amino acid residues are critical for ligand selectivity.  For example, amino 
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acid residue Trp318 located in extracellular loop (EL) 3 of the mu-opioid receptor is a 
major contributor to the selectivity of mu-opioid receptor antagonists to the mu-opioid 
receptor.11  It is important to note that Trp318 is not conserved in the delta- and kappa-
opioid receptors.11  Therefore, the addition of certain structural features to the backbone 
of naltrexone that might interact with EL3 of the receptor may lead to some novel 
antagonists with high selectivity to the mu-opioid receptor. 
The focus of this project is the design, chemical synthesis and pharmalogical 
evaluation of selective and reversible non-peptide mu-opioid receptor antagonists that 
carry structural features to interact with EL3 of the mu-opioid receptor.  The molecular 
design of the compounds is based on our previous molecular modeling studies of some 
selective mu-opioid receptor agonists and irreversible mu-opioid receptor antagonists.  
Based on the information obtained from the molecular modeling studies, a series of new 
ligands will be designed as mu-opioid receptor antagonists.  The newly designed ligands 
will be chemically synthesized and further characterized through various in vitro 
pharmacology studies, including competition radioligand binding assays for the three 
opioid receptors and functional assays to determine the possible efficacy of the ligands. 
The development of highly selective, non-peptidyl, and reversible mu-opioid 
receptor antagonists will benefit the treatment of dependence and addiction on opioids 
with fewer side effects.  Furthermore, these compounds can be used as probes to 
characterize the mu-opioid receptor and in the long run benefit the development of new 
analgesics with decreased adverse side effects. 
  
 II. Background 
 
1. Brief Introduction to the Mu-Opioid Receptor 
 The existence of different types of opioid receptors was proposed in 1973 by 
Terenius and later confirmed by other research groups using stereospecific radioligand 
binding assays.12-14  In 1981, three distinct types of opioid receptors were identified and 
classified as mu-, delta- and kappa-opioid receptors based on results of the behavioral and 
bioassay studies.15,16  All three opioid receptors have been cloned and the amino acid 
residue sequences of their cDNA has been determined between 1993 and 1994.17  Further 
pharmacological characterization revealed that the mu-opioid receptor mediates the 
analgesic effect of morphine.18,19
 
1.1 Structure and Signal Transduction of the Opioid Receptor 
The opioid receptors belong to the G-protein coupled receptor (GPCR) 
superfamily in the rhodopsin subclass.  Opioid receptors (Figure 1) are integral 
membrane proteins made up of seven transmembrane (TM) spanning alpha-helices 
connected by three intracellular loops (IL) and three extracellular loops (EL).20  
5 
6 
 
Figure 1. Model of the human mu-opioid receptor.21
 
The seven transmembrane regions of the receptor allow signal transduction for 
many small molecules, peptide transmitters, and modulators.  The interaction of the 
receptor with the guanine nucleotide-binding proteins (G-proteins) mediates signaling for 
opioid receptors.22  The G-protein is a heterotrimeric protein composed of three subunits, 
the Gα, Gβ and Gγ subunits.  Opioid receptors interact preferentially with the pertussis 
toxin sensitive G-proteins of the Giα and Goα families.22   
The Gα, Gβ and Gγ subunits activate when an agonist binds to the receptor and a 
conformational change takes place (Figure 2).  This conformational change promotes the 
exchange of GDP with GTP at the Gα subunit.  The G-protein dissociates into a GTP-
bound Gα subunit and a Gβγ subunit and both will activate downstream second messenger 
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pathways.  Deactivation of the receptor occurs when GTPase located in the Gα domain 
hydrolyzes the GTP subunit to a GDP subunit followed by re-association with the Gβγ 
subunit.23
 
Figure 2. The activation cycle of a GPCR.24
  
 Activation of the opioid receptor mediates the inhibition of adenylyl cyclase 
activity caused by the GTP-bound Gα subunit.25  The acute inhibition of adenylyl cyclase 
reduces the production of cyclic adenosine monophosphate (cAMP) resulting in the 
reduction of voltage-dependent current and neurotransmitter release.  The threshold of 
voltage-dependent ion channels shifts to more negative potentials when cAMP levels 
decrease.  Therefore, there is a decrease in neuron excitability.26  In addition, the Gβγ 
subunit of opioid receptors mediates the reduction of cellular excitability through 
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membrane hyperpolarization caused by the activation of potassium conductance and the 
inhibition of voltage-gated calcium channels.27,28  
 
1.2 Distribution of the Mu-Opioid Receptor in the CNS 
 Anatomical localization of opioid receptors was first investigated using 
radioligand autoradiography techniques.29  Later, cloning technology and 
immunohistochemical analysis has allowed higher resolution to investigate anatomical 
distributions and expression levels of opioid receptors at the plasma membrane.30,31  The 
opioid receptors are widely distributed in the central nervous system (CNS) and in the 
peripheral sensory and autonomic nerves.32  Studies have shown that the mu-opioid 
receptor is expressed throughout the CNS including the cortex, hypothalamus, midbrain 
periaqueductal gray (PAG) matter, and rostral ventromedial medulla (RVM).33,34  Mu-
opioid receptors control the pain transmission pathway directly by acting in the 
superficial layers of the dorsal horn.34  At the same time, the mu-opioid receptor as well 
as the kappa-opioid receptors are widely distributed on the wall of the gastrointestinal 
tract.35
 
1.3 Pharmacological Effects Mediated by the Mu-Opioid Receptor 
Activation of opioid receptors by endogenous peptides is involved in regulation of 
both behavioral and homeostatic functions, including nociception, food intake, 
respiration, reward mechanisms, and gastrointestinal motility.36  Through the use of 
transgenic mice lacking each opioid receptor, the mu-opioid receptor was confirmed to 
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mediate the acute effects of most clinically relevant opioid drugs including analgesia, 
respiratory depression, locomotor stimulation, and chronic effects such as physiological 
withdrawal signs.37  The activation of mu-opioid receptors specifically mediates the 
analgesic actions of opioid agonists.34  The role of endogenous opioids in pain 
suppression provides an important insight into the biology of opioid analgesics.  
Morphine, the prototypical opioid analgesic, does not simply inhibit the pain-
transmission pathways; it mimics the action of the endogenous opioid peptides released 
in response to a specific stimulus such as pain.34
It is well known that the chronic use of opioid analgesics results in the 
development of tolerance, which is defined as a loss of effect following repeated 
treatments such that a higher dose is required for an equivalent effect.34  Dependence is 
another result from chronic use of opioid analgesics.  Interestingly, it has been proposed 
that dependence occurs with the discontinuation of opioid drugs and will manifest itself 
as a withdrawal syndrome.18
 
2. Mu-Opioid Receptor Antagonists 
 Mu-opioid receptor agonists like morphine have been used for many years and are 
still used as the first line therapy in the treatment of moderate to severe pain.36  Despite 
the clear benefits from the use of mu-opioid receptor agonists, severe side effects have 
been associated with these drugs.  These side effects, including respiratory depression, 
addiction and dependence, associated with opioid agonists have been determined to come 
from the interactions with the mu-opioid receptor.   
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At present, there are several pharmacotherapies available for maintenance 
treatment of opioid addiction.  These pharmacotherapies include opioid receptor 
antagonists with low selectivity like naltrexone and naloxone.  Although they are 
commonly used for treatment of the adverse effects associated with mu-opioid receptor 
agonists, naloxone and naltrexone have some side effects due to their lack of selectivity.  
Therefore, selective opioid antagonists are important in order to eliminate interactions 
with other opioid receptors. 
Cyprodime is another opioid antagonist used mainly in pharmacological studies 
due to its moderate selectivity to the mu-opioid receptor.  However, cyprodime has lower 
affinity to the mu-opioid receptor compared to naloxone and naltrexone.  Other types of 
mu-opioid receptor antagonists include peptide ones, such as CTAP and CTOP, and 
irreversible non-peptidyl ones, e.g. β-FNA.  These peptides and irreversible non-peptidyl 
compounds are not used for medicinal purposes due to various issue associated including 
rapid metabolism and inactivation of the receptor indefinitely.  Therefore, the 
development of reversible and selective non-peptidyl mu-opioid receptor antagonists will 
be beneficial in the treatment of the adverse effects associated with opioid agonists.  
 
2.1 Prototypical Mu-Opioid Receptor Agonist: Morphine 
Activation of the mu-opioid receptor by opioid agonists has been associated with 
various undesirable side effects.  Some of these side effects include dependence, 
sedation, respiratory depression, seizure, constipation, and opioid bowel dysfunction.38  
Despite these serious effects associated with opioid agonists such as morphine (1; Figure 
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3), the rate of their use for moderate to severe pain has steadily increased in recent 
years.39   
HO
N
OH
O
1
OH
 
Figure 3. Structure of the mu-opioid receptor agonist: morphine (1). 
 
Morphine is the principal active agent of opium and is a very potent mu-opioid 
receptor agonist (Table 1).36  Morphine acts directly in the CNS to relieve pain and is the 
gold standard used to judge the analgesic properties of other mu-opioid receptor 
agonists.38
 
Table 1. Binding affinities of morphine (1) for the opioid receptors.36  
 Ki μ (nM) Ki δ (nM) Ki κ (nM) Ratio δ/μ Ratio κ/μ 
1 1.80 160 47.0 88.9 26.1 
 
The discovery of new pain medications has occupied both the academic 
community and pharmaceutical industry for the past two decades with little success.38  
Morphine and related compounds remain the drugs of choice for the treatment of 
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moderate to severe pain in the U.S.  Furthermore, many of the newer drugs are either in 
clinical trials or currently on market in alternative dosage forms of classical opioids.40
 
2.2 Naltrexone and Naloxone: Non-selective Opioid Receptor Antagonists 
 Opioid antagonists are commonly used as rescue medications to counteract the 
adverse side effects induced by opioid agonist overdose, mainly respiratory depression.  
They are also used clinically in the treatment of opioid dependence and alcoholism.41  To 
this date, there are only two FDA approved mu-opioid receptor antagonists, naloxone and 
naltrexone, for the treatment of adverse effects associated with opioid agonists.38 
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Figure 4. Structures of naloxone (2), naltrexone (3), naltrexone’s metabolite 6β-naltrexol 
(4), and buprenorphine (5).  
 
Naltrexone (3; Figure 4) is a competitive opioid receptor antagonist with low 
selectivity that falls into the morphinan structural series of opioids.  Naltrexone 
promiscuously binds with high affinity to the mu- and kappa-opioid receptors and binds 
with lower affinity to the delta-opioid receptor (Table 2).42  Naltrexone has been found to 
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be orally active with greater potency and longer duration of action than its counterpart 
naloxone (2; Figure 4).43  When naltrexone is administered orally, about 60% is 
eliminated within 42 h after administration.44  The mean naltrexone plasma levels decline 
very slowly and naltrexone still can be seen in the plasma 96 h after administration.45  
These properties make naltrexone suitable for the treatment of opioid dependence and 
provide an effective treatment for addicted patients.46  For over a decade, naltrexone has 
also been an approved treatment for alcohol addiction, although oral administration leads 
to poor patient compliance.47  When administered to an opioid-dependent person, acute 
withdrawal effects will precipitate.4  When naltrexone is administered orally, only 40% of 
the dose is bioavailable due to the first pass metabolism.48  In addition, poor compliance 
may be due to elevated plasma concentrations of the first pass metabolite 6β-naltrexol (4; 
Figure 4).  This metabolite has been linked to increased incidence of side effects and 
treatment dropout.49   
Naloxone is administered intravenously to reverse respiratory depression 
associated with overdose and analgesia from opioid agonists.  Although naloxone has 
lower affinity to the mu-opioid receptor compared to naltrexone, it still has the ability to 
precipitate withdrawal effects similar to naltrexone.  The oral bio-availability of naloxone 
is poor (only 2%) due to extensive first pass metabolism.50
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Table 2. Binding affinities of naloxone (2) and naltrexone (3) for the opioid 
receptors.42,51
 Ki μ (nM) Ki δ (nM) Ki κ (nM) Ratio δ/μ Ratio κ/μ 
2 1.90 32.6 3.06 17.2 1.61 
3 0.11 60.0 0.19 545 1.72 
 
The FDA recently approved Vivitrol, an extended-release formulation of 
naltrexone that is administered intramuscularly, for the treatment of alcohol addiction.  
The administration of Vivitrol results in lower plasma concentration of 6β-naltrexol, 
which leads to better patient compliance and a reduced side effect profile.47  Other 
treatments for opioid addiction include combination of naltrexone and buprenorphine.  
Buprenorphine (5; Figure 4) is a mu-opioid receptor partial agonist and allows a decrease 
in withdrawal symptoms during opioid detoxification since naltrexone may displace 
buprenorphine from the mu-opioid receptor more gradually due to similar affinities.52
 Although naloxone and naltrexone are effective treatments for a large number of 
disorders, including alcoholism and opioid dependence, they still have several 
pharmacokinetic issues.  Naloxone has very poor oral bioavailability and a short half-
life.53  On the other hand, naltrexone is associated with poor compliance due to the 
formation of the metabolite 6β-naltrexol.49  Both naltrexone and naloxone show low 
selectivity to the mu-opioid receptor exclusively and this may lead to other 
complications.  Cardiac arrhythmias and pulmonary edema may be linked to naloxone’s 
interaction with the kappa-opioid receptors.54  Also patients receiving naltrexone for 
opioid dependence exhibited higher than expected rates of overdose and suicide while 
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some reports have been linked to depression and dysphoria due to naltrexone’s 
interaction with the delta-opioid receptor.55
 
2.3 Cyprodime: Moderately Selective Mu-Opioid Receptor Antagonist 
Unlike naloxone and naltrexone that lack selectivity to the mu-opioid receptor, 
cyprodime (6; Figure 5) is a moderately selective mu-opioid receptor antagonist in vivo 
(Table 3).56  Cyprodime has been labeled with tritium resulting in a selective mu-opioid 
receptor radioligand with high affinity that has potential to be used as tool in probing mu-
opioid receptor mechanisms.  Although cyprodime is more selective for the mu-opioid 
receptor over the delta- and kappa-opioid receptors, it shows lower affinity for the mu-
opioid receptor compared to naloxone and naltrexone.  Further studies based on the 
structure profile of cyprodime did not yield any more selective mu-opioid receptor 
antagonists with higher affinity to the mu-opioid receptor.57   
 
OHO
N
OCH3
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6  
Figure 5. Structure of the mu-opioid receptor antagonist: cyprodime (6). 
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Table 3. Binding affinities of cyprodime (6) for the opioid receptors.56
 Ki μ (nM) Ki δ (nM) Ki κ (nM) Ratio δ/μ Ratio κ/μ 
6 5.40 245 2187 45.4 405 
 
2.4 Selective and Irreversible Mu-Opioid Receptor Antagonists 
 Through the use of selective or irreversible opioid antagonists as probes, opioid 
receptors and their functional mechanisms can be characterized.  The use of selective or 
irreversible antagonists allows for elimination of a particular receptor type.  Then the 
pharmacological properties of the remaining receptor types can now be observed.58,59  
Selective irreversible antagonists can be used in combination with agonists to estimate 
the relative efficacy and affinity of opioid agonists.  The most widely used irreversible 
mu-opioid receptor antagonist is beta-funaltrexamine.60
β-Funaltrexamine (β-FNA, 7; Figure 6) was described by Portoghese in 1981 as 
the first selective mu-opioid receptor antagonist.61  β-FNA binds to all three opioid 
receptors with high affinity.  However, β-FNA is an irreversible opioid antagonist only at 
the mu-opioid receptor in vitro, which acts as a site-directed alkylating agent that binds 
covalently to the mu-opioid receptor.61  The ability of β-FNA to alkylate the mu-opioid 
receptor selectively leads to depletion of the mu-opioid receptor population.38  β-FNA has 
been widely employed as a tool in the investigation of opioid receptor mechanisms.62
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Figure 6. Structure of β-FNA (7). 
 
 Highly selective and irreversible ligands such as β-FNA are widely used as 
affinity labels.  The design of β-FNA involved the attachment of chemically selective 
Michael acceptor group to a naltrexone-derived antagonist pharmacophore.63  Several 
factors need to be considered when creating an affinity label.  These factors include 
affinity of the ligand for the receptor recognition site, the location of the electrophilic 
center of the ligand, and the reactivity and selectivity of the electrophilic group.62  
Therefore, two consecutive recognition steps are involved in the covalent bonding and 
the proper orientation of the ligand with the receptor.64  The use of β-FNA illustrates that 
mu-opioid receptor agonists and antagonists have different binding sites.  The pre-
treatment with a mu-opioid receptor agonist, such as morphine, did not protect the 
receptor from β-FNA.  However, the introduction of a reversible mu-opioid receptor 
antagonist, such as naltrexone, effectively protected the receptor from alkylation by β-
FNA.65
The replacement of the 14-hydroxyl group of naltrexone with an amino group 
creates 14-aminonaltrexone (8; Figure 7), which displays potent antagonist activity both 
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in vivo and in vitro.38  The acylation of the 14-amino group leads to two more irreversible 
mu-opioid receptor antagonists, clocinnamox (C-CAM, 9; Figure 7) and methocinnamox 
(M-CAM, 10; Figure 7).66  Unlike β-FNA, both C-CAM and M-CAM act as potent 
opioid antagonists to all three of the opioid receptors.65
HO
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Figure 7. Structure of irreversible mu-opioid receptor antagonists: 14-aminonaltrexone 
(8), clocinnamox (9), and methocinnamox (10). 
  
The use of selective and irreversible antagonists for the mu-opioid receptor limits 
their use since they bind covalently with the receptor.  Therefore, reversible antagonists 
would be preferred since they temporarily “knock-out” the receptors during 
pharmacological studies and can be washed out from the binding locus to revive the 
receptor. 
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2.5 Selective Peptidyl Mu-Opioid Receptor Antagonists 
 Somatostatin is a widely distributed regulatory peptide that binds to various 
somatostatin receptors within the CNS and peripheral nervous system and is involved in 
many biological processes including binding to the mu-opioid receptor.67,68  Somatostatin 
was used as a conformational template centered on the tetrapeptide sequence Phe-D-Trp-
Lys-Thr for the design of a series of compounds that contains a β-turn that was found to 
be potent to the mu-opioid receptor.69  From the conformational template of somatostatin 
two compounds of penicillamine-containing octapeptides were designed and synthesized, 
D-Phe-C[Cys-Tyr-D-Trp-Orn-Thr-Pen]-Thr-NH2 (CTOP, 11; Figure 8) and D-Phe-
C[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 (CTAP, 12; Figure 8).70  Both compounds 
contain a disulfide linkage between the cysteine and penicillamine that provided a useful 
approach in improving selectivity of flexible peptides.70  The additional conformational 
constraint allows for an increase in molecular rigidity and an increase in metabolic 
stability compared with other endogenous opioid peptides.10  Radiolabeled CTAP has 
been shown to be stable in the blood and serum of rats with a half-life of 500 min.  The 
increased stability of CTAP is probably due to the penicillamine-cysteine disulfide 
linkage that allows for CTAP to become conformationally constrained and biologically 
active.71
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12   
Figure 8. Structure of selective peptidyl mu-opioid receptor antagonists: CTOP (11) and 
CTAP (12). 
 
 Although CTOP and CTAP are based on the somatostatin hormone, they both act 
as mu-opioid receptor antagonists with low affinity to the somatostatin receptor (Table 
4).72  CTAP has shown to reduce antinociception in mice and block the mu-opioid 
receptor without causing severe withdrawal symptoms.73  The use of radiolabeled CTAP 
has demonstrated its ability to cross the blood brain barrier (BBB) at therapeutic levels.71  
Although CTAP has shown some promise as a selective mu-opioid receptor antagonist 
compared to natural peptides, however, CTAP is also selective to the somatostatin 
receptor.  Even though CTAP is more stable compared to endogenous opioid peptides, it 
is still vunerable to enzymatic degradation to a lesser extent.10,74   
 
Table 4. Binding affinities of CTOP (11) and CTAP (12) for the opioid receptors.75,76
 Ki μ (nM) Ki δ (nM) Ki κ (nM) Ratio δ/μ Ratio κ/μ 
11 0.18 >1,000 >1,000 >5,555 >5,555 
12 2.30 365 >10,000 159 >4,348 
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 Since pharmacological studies require both in vivo and in vitro activity, the use of 
selective mu-opioid receptor peptides such as CTOP and CTAP are not as desirable as 
non-peptidyl mu-opioid receptor antagonists since they have a shorter half-life.  
Therefore, non-peptidyl mu-opioid receptor antagonists are preferred since they have the 
ability to penetrate the CNS and are less vunerable to metabolic inactivation compared to 
peptides.  
 
3. Application of the “Message-Address” Concept in the Design of Kappa-
Opioid Antagonists 
 Progress in opioid research has relied on the use of non-selective opioid 
antagonists like naloxone and naltrexone.  Both, naloxone and naltrexone are frequently 
used in the verification of opioid receptor interactions since they can induce antagonism 
with all three opioid receptors.77  Since the recognition of multiple opioid receptor types, 
the development of selective antagonists as tools to determine the selectivity of opioid 
agonists has become increasingly important.9
 The “message-address” concept has been used to design non-peptidyl selective 
kappa-opioid receptor antagonists like norbinaltorphine (Nor-BNI, 13; Figure 9) and 
GNTI (14; Figure 9) as tools in opioid research.9  Following this concept may allow the 
design of new selective mu-opioid receptor antagonists. 
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Figure 9. Selective kappa-opioid receptor antagonists: norBNI (13) and GNTI (14). 
 
3.1 Message-Address Concept 
 Schwyzer first proposed the “message-address” concept in his analysis of the 
structure-activity relationship of ACTH, adrenocorticotropic hormone, and related 
hormones.78  Peptide hormones within the same class contain a “message” sequence and 
an “address” sequence of amino acid residues, each being sequential and close to one 
another in the peptide chain.  The message component is responsible for signal 
transduction, while the address component provides additional binding affinity and is not 
essential for the transduction process.79  Therefore, each compound will contain a unique 
address component linked to a common message recognition component (Figure 10).80,81
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Figure 10. Message-address concept.  This concept is the basis for selectivity for ligands 
to a particular subtype of receptor.82  
 
 
3.2 Design of Selective Kappa-Opioid Receptor Antagonist 
 
 The “message-address” concept has been used to demonstrate opioid ligand 
selectivity.  First, this concept was enriched so that the “message” component is similar 
for all the opioid receptor subtypes.  Second, the “address” component is the primary 
determinant of selectivity among receptor subtypes.  GNTI (14, Figure 11), 5’-
guanidinonaltrindole, was one of the first selective kappa-opioid receptor antagonists 
designed utilizing the “message-address” concept.83  
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Figure 11. The conformational analysis of GNTI (14). 
  
 The “message” component of GNTI consists of the morphinan moiety; the 
“address” component consists of the guanidine moiety.  The guanidine moiety confers the 
selectivity of GNTI to the kappa-opioid receptor.  The indole ring acts as a “spacer” used 
to connect the “message” and “address” components.  GNTI is 5-fold more potent and 
selective than the prototypical kappa-opioid receptor antagonist norBNI.82 
Molecular modeling studies of GNTI with the kappa-opioid receptor suggested 
the involvement of Glu297 in the binding locus, which is located on the top of TM6.  
Since Glu297 is an acidic amino acid residue, it may interact with the guanidine moiety 
of GNTI.  The mutation of Glu297 to an alanine amino acid residue dramatically reduced 
the affinity of GNTI to the kappa-opioid receptor.59,84  Therefore, Glu297 is important for 
the recognition and selectivity of GNTI in the binding pocket of the kappa-opioid 
receptor.85   
 
 
25 
 
Another site-directed mutagenesis study was conducted to determine the 
significance of the acidic amino acid residue Glu297 for the selectivity of GNTI and 
norBNI to the kappa-opioid receptor over the mu-opioid receptor.  The study involved the 
mutation of the amino acid residue Lys303 in the mu-opioid receptor into a glutamate 
residue (K303E).  Lys303 in the mu-opioid receptor was found to be in an equivalent 
position compared to Glu297 in the kappa-opioid receptor.  It was found that the 
replacement of the lysine residue with the glutamate residue allowed the binding of 
norBNI and GNTI with much higher affinity to the mutated mu-opioid receptor then to 
the wild mu-opioid receptor.84
Alternatively, when Glu297 was mutated to a lysine residue in the kappa-opioid 
receptor (E297K), the binding affinities for both GNTI and norBNI were diminished to 
the mutated kappa-opioid receptor (Table 5).  These studies suggest that the kappa-
opioid receptor and the mutated mu-opioid receptor contain similar binding sites that may 
be the recognition or “address” site.  These binding sites were able to recognize the 
positively charged group in  GNTI and norBNI.84  This study highlights the significant 
role of the acidic amino acid residue, Glu297, of the kappa-opioid receptor in conferring 
ligand selectivity. 
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Table 5. Effects on the binding affinity of mutated amino acid residues Glu297, in kappa-
opioid receptor, and Lys303, in mu-opioid receptor using norBNI (13) and GNTI (14).84 
 
 Kiκ (nM) Kiκ [E297K] (nM) Kiμ (nM) Kiμ [K303E] (nM) 
13 0.12 12.5 101.9 0.77 
14 0.75 12.9 9.23 0.06 
 
 This successful application of “message-address” concept in the design and 
development of kappa-opioid receptor selective antagonists gives an insight in the 
development of mu-opioid receptor selective antagonists. 
 
4. Summary 
The application of ligands with high selectivity for each type of the opioid 
receptors is crucial for the understanding of the mechanism of opioid actions.  There are 
currently many mu-opioid receptor agonists available but morphine is still the most 
commonly used agonist.  Morphine acts at the mu-opioid receptor to produce analgesic 
effects.  However, it can cause other adverse effects including respiratory depression, 
dependence, and addiction.38  Therefore, the development of mu-opioid receptor 
antagonists is important in the maintenance treatment of opioid addiction. 
Currently, only two mu-opioid receptor antagonists, naloxone and naltrexone, are 
approved by the FDA for the treatment of adverse effects associated with opioid 
agonists.38  However, both naloxone and naltrexone carry low selectivity to the mu-
opioid receptor and may cause other adverse side effects due to their low selectivity.42,52  
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Other types of mu-opioid receptor antagonists have been developed including peptide 
ones and irreversible non-peptidyl ones.  However, peptides can undergo metabolism 
easier than non-peptides and irreversible antagonists limit the use of the compounds since 
they inactivate the receptor indefinitely.58,71 
The development of a non-peptide, reversible mu-opioid receptor antagonists is 
important for the treatment of dependence and addiction to opioid agonists.  These drugs 
seem to be more promising because they will have less interference with the normal 
function of the delta- and kappa-opioid receptors.  Such mu-opioid receptor selective 
antagonists may also be useful in the characterization of the mu-opioid receptor structure-
function relationship. 
 
 
 III. Project Design 
 
 The project, the development of selective non-peptidyl mu-opioid receptor 
antagonists, consists of four parts: molecular design, chemical synthesis, biological 
evaluation, and molecular modeling study.  The novel ligands will be designed based on 
the identification of important pharmacophore elements in several known opioid agonists 
and antagonists.  Chemical synthesis will be conducted to prepare the designed ligands.  
Next, in vitro pharmacology studies will be pursued in order to determine the affinity of 
these compounds for three types of opioid receptors.  Finally, molecular modeling studies 
will be carried out in order to visualize the binding modes of the ligands in the mu-opioid 
receptor. 
 
1. Molecular Design  
Applying the “message-address” concept, a comparative conformational analysis 
of several known mu-opioid receptor agonists and antagonists will be conducted to 
identify major pharmacophore elements, followed by docking studies of these ligands in 
a homology model of mu-opioid receptor to identify the unique amino acid residues in 
the binding locus.  To be noted, previous studies have shown that extracellular loops, 
especially EL2 and EL3, may be involved in the determination of ligand selectivity 
28 
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for opioid receptors based on the relatively low sequence homology level in the EL 
domains among the three opioid receptors.86                      
 
  1.1 Comparative Conformational Analysis of Mu-Opioid Receptor Agonists and 
Antagonists 
 The design of novel selective mu-opioid receptor antagonists will be based on a 
comparative conformational study utilizing highly selective mu-opioid receptor agonists 
such as fentanyl (15, Figure 12) and endomorphin 2 (16, Figure 12).   
As shown in figure 12, the phenylethyl moiety in fentanyl is orientated the same 
way as the tyrosine (Tyr) residue at the first position of endomorphin 2.  This suggests 
that it may be related to their agonist activity for the mu-opioid receptor and belongs to 
the “message” component of the molecule.  The N-phenyl ring connected to the 
propanamide group in fentanyl may overlap with the third amino acid residue, 
phenylalanine (Phe), of endomorphin 2.  This might be the “address” part of these 
molecules to recognize the mu-opioid receptor (please refer to message-address concept 
in the background on pages 20-23).   
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Fentanyl (15) Endomorphin 2 (16) Clocinnamox   (9) 
Figure 12. Comparative conformational analysis of selective mu-opioid receptor agonists 
and antagonists. 
   
The conformational analysis of clocinnamox (7), an irreversible mu-opioid 
receptor antagonist, shows a correlation with the above results.  The 17-
cyclopropylmethyl group in clocinnamox may be positioned similarly to the phenylethyl 
moiety of fentanyl and belongs to the “message” component of the molecule.  To be 
noticed, many mu-opioid receptor antagonists including GNTI, naltrexone, nalorphine 
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and clocinnamox carry similar size substitutions at the 17-position.  This may help 
explain why clocinnamox acts as an antagonist to the mu-opioid receptor while fentanyl 
acts as an agonist.  Therefore, the “message” component of these antagonists may be the 
cyclopropylmethyl group.  However, the p-chlorophenyl moiety at the 14-position of 
clocinnamox may overlap with the N-phenyl ring of fentanyl, the “address” component of 
the molecule.  This suggests that agonists and antagonists may share similar “address” 
components that confer their common selectivity to the mu-opioid receptor, while their 
“message” components are different due to the opposite signal transductions. 
 
1.2 Docking Studies in a Homology Model of the Mu-Opioid Receptor 
The results of the comparative conformational study between fentanyl, 
endomorphin 2, and clocinnamox will be verified using a homology model of the mu-
opioid receptor.  This model will be built based on the X-ray crystal structure of bovine 
rhodopsin.  Bovine rhodopsin, also a member of the GPCR superfamily, has a 30% 
sequence identity compared to the opioid receptors.87  Although the sequence homology 
level between opioid receptors and bovine rhodopsin are not very high, it is possible to 
build a plausible homology model of the mu-opioid receptor based on rhodopsin’s X-ray 
crystal structure.87   
Previously, a homology model was built for the mu-opioid receptor based on a X-
ray crystal structure of the dark state bovine rhodopsin (Figure 13).  The homology 
model of the mu-opioid receptor was further optimized in a membrane-aqueous system.87  
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The interactions between naltrexone and the homology model of the mu-opioid receptor 
have been well characterized.16 
 
Figure 13. Homology model of the mu-opioid receptor in a membrane-aqueous 
interface.87
 
The comparative conformational analysis study has been verified using docking 
studies where clocinnamox is docked into the binding pocket of the homology model of 
the mu-opioid receptor.  We have noticed that there is significantly low sequence 
homology in the EL2 and the EL3 in the three opioid receptors while these regions are 
important in the recognition and binding of opioid ligands.16,87  Docking studies of 
clocinnamox show that the 14-p-chlorophenyl moiety of clocinnamox (address part) is 
located in an aromatic area of the binding pocket at EL2 and EL3 locus (Figure 14). 
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Figure 14. Docking study of clocinnamox in the mu-opioid receptor homology model. 
 
The 14-p-chlorophenyl moiety in clocinnamox is located in an aromatic binding 
pocket of the mu-opioid receptor and is considered the “address” component of 
clocinnamox.  The amino acid residues Tyr210, Phe313, and Trp318, are not conserved 
in the delta- and kappa-opioid receptors.  Therefore, similar aromatic binding pockets 
may not exist in the delta- and kappa-opioid receptors.  Trp318 in EL3 has been 
determined, through site-directed mutagenesis studies and chimera opioid models, to be a 
significant contributor to the selectivity of the mu-opioid receptor agonists and 
antagonists.88   
Therefore, the hypothesis for this study is that a mu-opioid receptor ligand 
carrying an aromatic structural feature that may interact with EL3 of the receptor might 
lead to its high selectivity to the mu-opioid receptor.  Based on this hypothesis, a series of 
new ligands that may satisfy the requirements of the mu-opioid receptor binding pocket 
will be designed and synthesized to test their affinity towards the mu-, delta- and kappa-
opioid receptors.   
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1.3 Design of Selective Mu-Opioid Receptor Antagonists 
Based on the previous studies and analysis, a series of novel ligands as 14-O-
heterocylic substituted naltrexone derivatives are designed as mu-opioid receptor 
selective antagonists (Figure 15).  The hetero-aromatic moieties include pyridine, 
quinoline and isoquinoline, which are attached to 14-O-position of naltrexone by an ester 
bond.  The nitrogen atom in the hetero-aromatic moieties may act as hydrogen bond 
acceptors towards the extracellular binding locus of the mu-opioid receptor, since certain 
amino acid residues on EL2 and EL3, e.g. Tyr210 and Trp318, were found to be essential 
for ligand recognition through site-directed mutagenesis studies.87  It is also important to 
note that Trp318 is a significant contributor to the selectivity of the mu-opioid receptor 
agonists and antagonists.87 
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Figure 15. Designed 14-O-heterocyclic substituted derivatives of naltrexone. 
  
A second series of selective mu-opioid receptor antagonists, 6-N-heterocyclic 
substituted naltrexamines, were previously designed and synthesized in our laboratories 
for a similar purpose (manuscript submitted to the Journal of Medicinal Chemistry).89  
These antagonists contain a heterocylic moiety including pyridine, quinoline, and 
isoquinoline, linked at the 6-position of naltrexone through an amide bond (Figure 16).  
The ligands carrying either the α- or β-configuration have been chemically synthesized to 
determine if stereochemical arrangement plays an important role in the affinity and 
selectivity for the mu-opioid receptor. 
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Figure 16. 6-N-heterocyclic substituted derivatives of naltrexamine.
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The aromatic character of the heterocyclic moiety helps to provide an aromatic 
interaction to the aromatic binding pocket in the mu-opioid receptor.  The nitrogen atom 
may act as a hydrogen bond acceptor to probe possible formations of hydrogen bonds 
with the amino acid residue Trp318 of EL3 of the mu-opioid receptor.  Also, the 
stereochemical arrangement may play a very important role for the affinity, as well as the 
selectivity, of the ligand, based on previous compounds such as α-FNA and β-FNA.90  
Although β-FNA binds to the mu-opioid receptor irreversibly, its epimer α-FNA does not 
bind to the mu-opioid receptor irreversibly.  However, α-FNA can protect against β-FNA 
induced irreversible antagonism.91  This suggests that both α- and β-FNA interact with 
the same site in the mu-opioid receptor but only β-FNA properly aligns and binds in the 
mu-opioid receptor.90
 Both sets of compounds, 14-O-heterocyclic substituted naltrexone and 6-N-
heterocyclic substituted naltrexamine, have a phenyl and naphthalenyl compound 
designed to act as controls in order to test the hydrogen bonding hypothesis.   
 Both series of compounds have been designed to test the hypothesis that the 
addition of a heteroaromatic moiety to the backbone of naltrexone and naltrexamine may 
allow for the formation of a hydrogen bonding interaction with Trp318 in EL3 of the 
binding pocket of the mu-opioid receptor.  This additional interaction may allow for the 
creation of more selective mu-opioid antagonists. 
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2.  Chemical Synthesis 
 Chemical synthesis of the 14-O-heterocyclic substituted naltrexone derivatives 
will be conducted using synthetic pathways adapted from literature.92,93  The basic 
scheme consists of the direct coupling of the heterocyclic moiety to the 3- and 14-
position of naltrexone.  This is followed by the selective removal of the heterocyclic 
moiety at the 3-position of naltrexone (Scheme 1). 
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Scheme 1. The synthetic route of 14-O-heterocyclic substituted naltrexone derivatives.  
The heterocyclic moieties are represented by “R”.  Reagents and conditions: a. DMF, 
TEA, N2(g); b. 4% H2SO4 (aq), MeOH, NH4OH. 
 
3. Biological Evaluation of the 6-N-Heterocyclic Substituted Naltrexamine and 
14-O- Heterocyclic Substituted Naltrexone Derivatives 
 Following the synthesis of the two series of naltrexone derivatives, bioassays will 
be conducted to study the selectivity of these ligands for the opioid receptors.  Mono-
cloned opioid receptor expressed CHO and HEK293 cells will be utilized to conduct 
these assays.  The affinities of the ligands will be determined by conducting binding 
assays utilizing tritiated radioligands, [3H]DAMGO, [3H]NTI and [3H]Nor-BNI, for the 
mu-, delta-, and kappa-opioid receptors, respectively.  Functional assays, i.e. [35S]GTPγS 
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binding assay, will be applied to the naltrexone derivatives with at least 10-fold 
selectivity for mu- over delta- and kappa-opioid receptors to determine whether the 
compounds act as full agonists, partial agonists or  antagonists.  Ideally, a lead compound 
will be identified as a mu-opioid receptor antagonist with high selectivity for the mu-
opioid receptor over delta- and kappa-opioid receptors. 
 
4. Molecular Modeling Study 
 A homology model of the mu-opioid receptor will be adapted to illustrate the 
possible docking modes of the 14-O-heterocyclic substituted naltrexone derivatives in the 
mu-opioid receptor.  The mu-opioid receptor homology model will be reconstructed and 
revisited by the author of the thesis based on the X-ray crystal structure of the dark state 
bovine rhodopsin.94  Site-directed mutagenesis data and chimera opioid receptor data will 
be used to identify important amino acid residues in the binding pocket.  The 14-O-
heterocyclic substituted naltrexone derivatives will be docked into the hypothetical 
binding pocket using GOLD to visualize the interactions of the ligands with the mu-
opioid receptor.  The GOLD scores from the docking studies of these naltrexone 
derivatives will be analyzed together with the binding affinities obtained from the 
biological studies. 
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5. Summary of the Project Design 
In summary, a series of novel opioid ligands as 14-O-heterocyclic substituted 
naltrexone derivatives, will be designed based on molecular modeling studies on known 
mu-opioid receptor selective agonists and antagonists.  These naltrexone derivatives will 
contain heteroaromatic moieties including pyridine, quinoline, and isoquinoline moieties 
at the 14-O-position of naltrexone that may form a hydrogen bonding interaction with an 
aromatic binding locus in EL domain of the mu-opioid receptor.  Next, compounds in this 
series, will be synthesized and the affinities will be determined for all three opioid 
receptors using in vitro biological assays.  Finally, a homology model of the mu-opioid 
receptor will be built based on the X-ray crystal structure of the dark state bovine 
rhodopsin.  Docking studies of the 14-O-heterocyclic substituted naltrexone derivatives 
will be conducted in order to visualize the interactions between the mu-opioid receptor 
and these ligands.   
In conclusion, the purpose of this study is the molecular design, chemical 
synthesis, biological evaluation and molecular modeling study of selective non-peptidyl 
mu-opioid receptor antagonists.  This project may lead to the development of more 
selective mu-opioid receptor antagonists with reduced adverse effects seen with other 
opioid antagonists like naltrexone and naloxone. 
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IV. Results and Discussion 
 
 
  
1. Chemical Synthesis of 14-O-Heterocylic Substituted Naltrexone Derivatives 
1.1       Chemical Synthesis Routes 
 Depending on commercially availability of the precursors of the 14-O-
heterocyclic moiety of naltrexone, one of the two synthetic routes is adapted from 
literature to synthesize the 14-O-heterocyclic substituted naltrexone derivatives.92,93  The 
first synthetic pathway involves the direct coupling reaction of an acyl chloride with 
naltrexone (Scheme 2A), while the second involves the in situ conversion of a carboxylic 
acid to an acyl chloride prior to the coupling reaction (Scheme 2B).   
 The heterocyclic moiety is first added to both the 3- and 14-positions of 
naltrexone, 17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one, to 
generate the di-substituted naltrexone intermediate (Scheme 2).  The following step 
involves the chemoselective removal of the heterocyclic moiety at the 3-position.  After 
the purification of the naltrexone derivatives by column chromatography, the target 
products are converted into hydrochloride salts.  The final yields of these compounds 
vary between 10 and 70% (Table 6). 
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Scheme 2. The synthetic route for the 14-O-heterocyclic substituted naltrexone 
derivatives.  
A. The direct coupling of an acyl chloride heterocyclic moiety with naltrexone.   
B. The conversion of a carboxylic acid heterocyclic moiety to an acyl chloride moiety, in 
situ followed by coupling with naltrexone.  
Reagents and conditions: a. DMF, TEA, N2 (g), 100 ºC, 4 h; b. 4% H2SO4 (aq), MeOH, 
rt, 4h;  
c. NH4OH, pH 7; d. SOCl2 ex., N2 (g), 80 ºC, 3 h; e. toluene, in situ; f. 2, DMF; g. H+; h. 
pH 7. 
 
The next step is the same for both routes A and B for all of the compounds.  The 
acyl chloride, commercially available or prepared in situ, is heated at reflux with 
naltrexone and TEA in DMF (solvent) for up to 4 h at 100 °C under nitrogen atmosphere.  
The solvent is then removed and the residue is dissolved in methanol and a 4% H2SO4 
aqueous solution, to selectively remove the heterocyclic moiety attached to the 3-position 
of naltrexone skeleton.  This step of the reaction took up to 4 h at room temperature.  A 
weak base (NH4OH) is then applied to neutralize the mixture.  The solvent is then 
removed and column chromatography is conducted to separate out the final product.  The 
yields for these compounds vary (Table 6).  
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Table 6. Percent yield of 14-O-heterocyclic substituted naltrexone derivatives.  
Compound 14-O-heterocyclic 
Substituent 
Route Percent Yield 
(%) 
17 
N  
B 50 
18 N
 
A 69 
19 
N  
A 24 
20 
 
A 10 
21 
N  
A 24 
22 
N
 
A 17 
23 
N  
B 22 
 
24 A 7 
 
1.2  The Synthesis of Acyl Chloride 
  In route B, the conversion of a carboxylic acid to an acyl chloride is necessary 
because acyl chlorides are good electrophiles, and therefore very reactive.  Both the 
oxygen and chlorine on the carbonyl carbon of the acyl chloride are strong electron 
withdrawing groups, allowing the carbonyl carbon to carry partial positive charge.  This 
will allow a weak nucleophile to attack the carbonyl carbon atom.  The hydroxyl group 
on carboxylic acids are not very good leaving groups and do not react in nucleophilic 
substitution reactions except when the hydroxyl group is protonated to give water, a good 
leaving group.94  To prevent protonation of the carboxylic acid, the environment is made 
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basic with the use of triethylamine (TEA), which contains a tertiary amine that can 
neutralize hydrochloric acid generated from the reaction through the formation of the salt 
triethylamine hydrochloride.92,93  
 The conversion reaction in step d in scheme 2 involves heating at reflux the 
carboxylic acid with thionyl chloride (SOCl2) under a nitrogen atmosphere.95  All the 
components are pre-dried in order to ensure the reaction was free of water.  The reaction 
mixture is heated with an excess amount of SOCl2 at 80 °C for about 3 h.96  Then, toulene 
is added and distilled in order to remove any excess of SOCl2.92,93  
 
1.3 Chemoselective Deprotection of 3-O-Substitution 
The addition of the heterocylic moiety to the skeleton of naltrexone is a “one-pot” 
reaction.  Therefore, both the 3- and 14-positions contain the heterocyclic moiety after 
the direct coupling reaction of the substituent with naltrexone.  A mildly acidic solution 
(dilute H2SO4 solution) is used to selectively cleave the substituent at the 3-position but 
still maintain the substitution on the 14-position of the naltrexone skeleton.  The phenyl 
ester moiety on the 3-position is highly unstable in acidic and in basic conditions, and can 
be readily cleaved.97  However, the substituent at the 14-position is only stable under 
mild acidic conditions and very labile in basic conditions.  This is due to the 14-position 
being a tertiary ester and is very unstable to basic hydrolysis.   
 Substitution on both the 3- and 14-positions requires a 2:1 ratio of acyl chloride 
substituent to naltrexone.  This is due to the 3-position of naltrexone having more 
accessibility to the substitution compared to the 14-position.  The 14-position contains a 
 45
 
 
tertiary alcohol and is also hindered by the methylcyclopropyl group.  Therefore, the 3-
position is substituted first followed by the 14-position. 
 
1.4 Methods for the Synthesis and Deprotection of Compounds 17, 20 and 24  
Although most of the compounds are synthesized in the above manner, some 
difficulty is encountered in the synthesis of compounds 17, 20 and 24.  The synthesis of 
compound 17 involves the conversion of picolinic acid to an acyl chloride.  The first few 
attempts produced a thick black residue and the reaction mixture probably is degraded.  
Therefore, conversion of the carboxylic acid to an acyl chloride is ran overnight followed 
by heating at reflux with naltrexone under a nitrogen gas atmosphere.  Instead of adding 
the dilute acid to cleave the substitution on the 3-position of naltrexone, column 
chromatography is used to separate out the target compound.  The final compound is 
isolated as a dark brown residue and not a powder like most of the other 14-O-
heterocyclic substituted naltrexone derivatives. 
 Compounds 20 and 24 are the control compounds.  Problems are found in the 
deprotection step.  After these two compounds are heated at reflux with naltrexone, a di-
substituted product was formed and there was difficulty in the removal of the 
heterocyclic moiety at the 3-position.  This may be due to the overall stability of the 
compound.  Several different attempts have been made to try to remove the heterocyclic 
moiety at the 3-position (Table 7). 
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Table 7. Deprotection conditions used to prepare compounds 20 and 24. 
Attempt Condition Reaction Time Overall Results 
1 Dilute acid (H2SO4)  24 hours Di-substituted product 
2 
Titration of sample from 
attempt 1 from pH 4 to 1 with 
addition of 1N H2SO4 
 
Overnight Di-substituted product 
3 
Heat mixture to 50 °C under 
nitrogen protection 
 
Overnight Di-substituted product 
4 
Addition of 5 mg sodium 
bicarbonate and dissolved in 
THF 
 
Overnight Di-substituted product 
5 
Dissolve in THF and potassium 
carbonate at room temperature 
 
Overnight Final mono-substituted product 
 
 Attempts 1 to 4 (Table 7) did not accomplish the removal of the substituent at the 
3-position.  However, the final attempt was successful.  Basically, THF and potassium 
carbonate mixture is separated into two layers: K2CO3 saturated water layer and THF 
layer.  The compound is isolated from the water layer and purified using column 
chromatography. 
 All the compounds are converted into dihydrochloride salts and completely dried 
using the vacuum pump prior to characterization by nuclear magnetic resonance (NMR), 
infrared spectroscopy (IR), mass spectrometry (MS) and melting point determination.  
All the compounds are evaluated for their affinity to all three opioid receptors through 
radiolabeled competition binding assays, and their efficacy for the mu-opioid receptor 
through [35S] GTPγS binding assay. 
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1.5 Verification of Dihydrochloride Salts 
 After the synthesis of the 14-O-heterocylic substituted naltrexone derivatives, 
they are converted into dihydrochloride salts through the addition of 2.2 equivalents of 
1.25 M hydrochloric acid in methanol.  However, the control compounds 20 and 24 are 
converted to mono-hydrochloride salts.  In order to verify whether these compounds are 
in the mono- or dihydrochloride salt form, 1H-NMRs are taken for both the free base and 
salt form of each compound.  If the compound is a di-hydrochloric salt, then there should 
be a difference in the chemical shifts between the free base and salt form in the 
heterocyclic substituent of the compounds. For each compound, the differences between 
the chemical shifts in the free base versus the salt form of the heterocylic substituent are 
observed (Table 8 and Table 9).  The chemical shifts of the heterocyclic substituent in 
the salt form are shifted down field compared to the free base form.  There is no major 
difference in the chemical shifts of the salt form and free base form of the two control 
compounds 20 and 24. 
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Table 8. The difference of the chemical shifts between the salt and free base forms of the 
first series of 14-O-heterocyclic substituted naltrexone derivatives. 
OHO
N
O
O
R
O
 
 
Compound 17 18 19 20 
 Substituent (R) 
 
 
   
Positions:     
2 - 0.34 0.07 0.00 
3 0.90 0.72 - 0.12 
4 0.60 - 0.69 0.11 
5 0.91 0.72 0.76 0.12 
6 0.36 0.34 0.42 0.00 
* The change in the chemical shifts of the salt and free base was determined by δsalt-δfree 
base.
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Table 9. The difference of the chemical shifts between the salt and free base forms of the 
second series of 14-O-heterocyclic substituted naltrexone derivatives. 
 
OHO
N
O
O
R
O
 
21 Compound 22 23 24 
 Substituent (R) 
 
 
Positions:     
1 0.14 N N 0.16 
2 N - 0.03 - 
3 - 0.86 - 0.10 
4 0.04 0.89 0.51 0.11 
5 0.12 0.95 0.40 0.19 
6 0.12 1.16 0.26 0.19 
7 0.12 1.29 0.49 0.10 
8 0.19 
* The change in the chemical shifts of the salt and free base was determined by δsalt-δfree 
base.
1.12 0.17 0.10 
 
 
 50
 
 
 All the compounds show a difference greater than 0.30 ppm in the chemical shifts 
between the salt and free base form except for compound 21.  Therefore, according to the 
data it can be assumed that all compounds are dihydrochloride salts except that 
compound 21 and the controls 20 and 24 are mono hydrochloride salts.   
It has been reported that environmental change can cause the complete 
conformational conversion of an amide skeleton upon the addition of acid.98  An N-
methyl amide containing N- 2,6-pyridinedicarboxamide moieties (43) that can switch its 
conformation depending upon the acceptor ability of the solvent.  With the addition of 
trifluoroacetic acid (TFA) to the amides, a lower field shift in the aromatic protons can be 
observed (Figure 17).   The addition of TFA to compound 43 causes the nitrogen atom in 
the pyridine ring to lie in the syn position with respect to the carbonyl group due to 
hydrogen bond formantion.98 
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Proton Shift (ppm) 
 
 
 
Proton Assignment 43 44 
Difference in 
chemical shifts 
3 7.60 7.60 0.00 
4 7.73 8.43 0.70 
5 7.24 8.04 0.80 
6 7.31 7.91 0.60 
Figure 17.  Difference in proton chemical shifts for N-2,6-pyridinedicarboxamide 
moieties with the addition of TFA (150 equiv).98  The difference in chemical shifts was 
determined by δ44-δ43.
 
 
Mass spectrometry was also conducted for all of the compounds.  The major peak 
was found to be the mono-protonated 14-O-heterocyclic substituted naltrexone 
derivatives.  The second major peak was determined to be mono-protonated naltrexone 
conjugated with the chloride ion.  For some of the compounds the di-protonated product 
can be seen but the relative intensity was low. 
 
2. Pharmacological Studies of 14-O-Heterocyclic Substituted Naltrexone 
Derivatives 
 In order to determine the affinities of these newly synthesized derivatives of 
naltrexone, several different radiolabeled binding assays were conducted.  First, a 
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saturation binding assay was used to determine the affinity of the radioligand used for 
each receptor and the approximate amount of receptors in the different monoclonal 
receptor expressed cell lines.  This was followed by competition binding assays to all 
three opioid receptors to determine the 14-O-heterocyclic substituted naltrexone 
derivatives’ affinity and selectivity.  Finally, the compounds underwent a functional 
assay to determine their potential agonist activity. 
 
2.1 Cell Culture of Cell Lines Over-expressing Opioid Receptors 
 Before any of the compounds were evaluated in the different binding assays, cell 
lines expressing the three opioid receptors were cultured and harvested for use in the 
assays.  For the mu- and kappa-opioid receptors, CHO cell lines were used.  For the 
delta-opioid receptor several different cell lines were used including HEK293, CHO and 
NG108-15 cell lines.  The CHO cell lines were cultured in DMEM/F12 media containing 
5% fetal bovine serum (FBS), 0.2 mg/mL geneticin (G418) and 1% penicillin-
streptomycin except 10% FBS was used for the DORCHO cell lines.  The HEK cell lines 
were cultured in DMEM media with 8% FBS, 0.2mg/mL G418, 1% penicillin-
streptomycin, and 1.5 mM HEPES.  The NG108-15 cell lines used DMEM media with 
10% FBS, 1% penicillin-streptomycin, 0.2 mg/mL G418 and 100x HAT.99,100
  
2.2      Saturation or Scatchard Radiolabeled Binding Assay 
 In order to characterize the receptors, a saturation or scatchard binding assay was 
used to determine the Bmax of the receptors for each cell line and Kd for the radiolabeled 
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ligands for their respective receptors.  Bmax is the maximum number of binding sites that 
can be bound by the radioligand and is a measure of receptor density in the tissue 
reported in pmol/mg.101  Kd is the affinity of the radioligand for the particular receptor 
and is the concentration of radioactive ligand required to occupy 50% of the receptors.  
Kd is reported in molar concentration units, in this case all of the Kd values were 
reported in nanomolar concentration units.  The saturation assay was performed for the 
CHO cell lines expressing the delta-opioid receptor (DORCHO) and the kappa-opioid 
receptor (KORCHO), and HEK cell lines expressing the delta-opioid receptor 
(DORHEK) all from the University of Minnesota.  For all the other cells lines, NG108-15 
(delta-opioid receptor) and mu-opioid receptor (MORCHO) from Virginia 
Commonwealth University (VCU) and delta-opioid receptor (DORCHO) from Temple 
University, the Bmax had already determined and used without further testing (Table 
10). 
 The radioligands used in all the assays are highly selective for their corresponding 
receptors.102  For the mu-, delta- or kappa-opioid receptors [3H] NLX, [3H] NTI or [3H] 
Nor-BNI were used respectively.  The saturation assay involves the competition of the 
radiolabeled ligand at different concentrations with the same drug, except it is unlabeled 
(cold), in excess for the corresponding receptors.  However, the cold drug used for the 
mu-opioid receptor was naltrexone. 
 Naltrexone can be used as the cold ligand instead of naloxone because naltrexone 
has about 10-fold higher affinity for the mu-opioid receptor compared to naloxone.42,51  
The cold ligand used to determine the non-specific binding needs to have high affinity for 
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its receptor.  Also, naltrexone and naloxone have comparable affinity to all three opioid 
receptors.42,51     
Table 10. Bmax and Kd for the different mono-cloned opioid expressed cell lines 
determined by saturation binding assay.   
 
Cell Line 
 
Bmax 
(pmol/mg) 
Kd 
(nM) 
MORCHO 3.00 2.00 
DORCHO (Temple) 5.80 * 
DORCHO (Minnesota) 1.21 0.46 
DORHEK 1.51 0.36 
KORCHO 3.37 0.65 
* Saturation assay was not completed for the DORCHO cells from Temple University.  
The Bmax was already determined and the Kd was assumed to be similar to the other 
cells that express the delta-opioid receptor. 
 
2.3     Competition Binding Assay 
 The competition binding assays were conducted for all the three opioid receptors 
in order to determine the binding affinities for naltrexone and the naltrexone derivatives.  
From this assay, IC50 values were determined and converted to Ki values using the 
Cheng-Prusoff equation.103  The same radioligands and cold drugs from the saturation 
binding assays were used in this assay.  However, this time the concentration of the 
naltrexone derivatives were varied, while the radioligand concentration was between 1 to 
2 times their Kd values. 
 
A. Mu-Opioid Receptor 
 The selectivity of the 14-O-heterocyclic substituted naltrexone derivative for the 
mu-opioid receptor was determined using [3H]NLX as the radioligand (2 nM) to compete 
with the naltrexone derivatives.  The non-specific binding was determined by an excess 
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of cold naltrexone at a concentration of 10 μM.  The MORCHO (from Dr. Selley’s 
laboratory at VCU) cells were used to determine the affinity of the naltrexone derivatives 
to the mu-opioid receptor.  About 10 to 15 μg of protein was added to each tube.  A 
Bradford protein determination assay was used to determine and adjust the concentration 
of protein required for the assay.104  The total volume of this assay was 500 μL.  The 
incubation time for this assay was 120 minutes in a 37 °C water bath.  Various 
concentrations of the naltrexone derivatives were tested to determine their Ki values.  
After incubation, the reaction was quenched with cold tris buffer.  A Brandel harvester 
was used to separate the bound from the free radioligand.  The results were determined 
utilizing a scintillation counter.  Ki
 
values are the result of triplicate determinations. 
 
B. Delta-Opioid Receptor 
The selectivity of the 14-O-heterocyclic substituted naltrexone derivative for the 
delta-opioid receptor was determined using [3H]NTI as the radioligand (0.5 nM) to 
compete with the naltrexone derivatives.  The non-specific binding was determined by an 
excess of cold naltrindole (NTI) at a concentration of 10 μM.  Although several different 
cell lines were utilized in this assay, only the DORCHO (from Temple University) cells 
were used to determine the ligands affinity.  About 10 to 20 μg of protein was added to 
each tube.  A Bradford protein determination assay was used to determine and adjust the 
concentration of protein required for the assay.104  The total volume of this assay was 
1000 μL.  The incubation time for this assay was 120 minutes in a 37 °C water bath.  
Various concentrations of the naltrexone derivatives were tested to determine their Ki 
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values.  After incubation, the reaction was quenched with cold tris buffer.  A Brandel 
harvester was used to separate the bound from the free radioligand.  The results were 
determined utilizing a scintillation counter.  Ki
 
values are the result of duplicate 
determinations.  
 
C. Kappa-Opioid Receptor 
 The selectivity of the 14-O-heterocyclic substituted naltrexone derivative for the 
kappa-opioid receptor was determined using [3H]Nor-BNI as the radioligand at a 
concentration of 0.6 to 1.2 nM, about 1 to 2 times the Kd value determined in the 
saturation assay.  The non-specific binding was determined by an excess of cold nor-BNI 
at a concentration of 10 μM.  The KORCHO cells were used and about 20 to 30 μg of 
protein was added to each tube.  A Bradford protein determination assay was used to 
determine and adjust the concentration of protein required for the assay.104  The 
incubation time for this assay was 120 minutes in a 37 °C water bath.  The total volume 
of this assay was 500 μL.  Various concentrations of the naltrexone derivatives were 
tested to determine their Ki value.  After incubation, the reaction was quenched with cold 
tris buffer.  A Brandel harvester was used to separate the bound from the free radioligand.  
The results were determined utilizing a scintillation counter.  Ki
 
values are the result of 
triplicate determinations. 
 There were a couple problems in the assay dealing with the radioligand.    
[3H]Nor-BNI is very unstable and was kept cold in the presence of nitrogen gas.  Also, 
the [3H]Nor-BNI was dissolved in 5:2 toulene:ethanol.  Toulene at very high 
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concentrations can disrupt cellular membranes.105  Therefore, the toluene:ethanol solvent 
was removed from the radioligand under vacuum pressure in an ice water bath for about 
8 to 10 h.  After the radioligand was completely dry, it was re-dissolved in ethanol.  Also 
a small amount of cold nor-BNI was added in order to dilute the concentration of 
[3H]Nor-BNI to a lower specific activity since it is very unstable at a high specific 
activity.  Nitrogen gas was added to the [3H]Nor-BNI in ethanol to help prevent further 
degradation.  This process was conducted for small batches of [3H]Nor-BNI, about 100 to 
150 μL, at a time.  
 Another problem seen in the assay was that the total amount of radioligand bound 
was between 15 to 20% of the total amount of radioligand added (standards).  In order to 
compensate for this problem, the total volume was increased from 0.5 to 1 mL and the 
amount of [3H]Nor-BNI was doubled from 0.6 to 1.2 nM, 2 times the Kd value.  This 
helps reduce the radioligand bound to between 7 to 8%.  
  
3. [35S]GTPγS Functional Binding Assay for the Mu-Opioid Receptor 
A functional assay was used to compare the agonist activity of the naltrexone 
derivatives to the mu-opioid receptor compared to DAMGO, a full mu-opioid receptor 
agonist.  From this assay, the potency, EC50, and the intrinsic efficacy, Emax, can be 
determined.  The EC50 is the molar concentration of an agonist to produce 50% of the 
maximal possible effect.  The Emax is the maximum effect of the agonist.106  DAMGO 
has an Emax value of 366% stimulation of receptor and represents 100% agonist activity.  
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All the naltrexone derivatives were compared to DAMGO’s Emax value in order to 
determine whether these compounds are agonists, partial agonists, and antagonists. 
The agonist activity of the naltrexone derivatives for the mu-opioid receptor was 
determined using [35S]GTPγS as the radioligand.   [35S]GTPγS was diluted so the final 
DPM count is about 125,000.  The non-specific binding was determined using an excess 
of cold gamma-GTP at a concentration of 20 μM.  GDP was also added to all the tubes at 
a concentration of 10 μM in order to obtain optimal agonist-stimulated binding.  The 
MORCHO cells were used and the approximate amount of protein added to each tube is 
between 9 to 10 μg in the assay.  A Bradford protein determination assay was used to 
determine and adjust the concentration of protein required for the assay.104  Finally, TME 
buffer with Na+ was utilized to improve agonist stimulated binding.107  The incubation 
time for this assay was 90 minutes in a 37 °C water bath.  The concentration of the 
naltrexone derivatives tested was between 0.0001 nM to 10,000 nM.   
 
4. Competition Binding Assay Results for 14-O-Heterocyclic Substituted 
Naltrexone Derivatives 
4.1 14-O-Pyridinyl Substituted Naltrexone Derivatives 
 The results for the first set of compounds, 14-O-pyridinyl substituted naltrexone 
derivatives, show that all of the compounds have nanomolar and subnanomolar affinity 
for the mu-opioid receptor.  More importantly, the first set of naltrexone derivatives 
display higher selectivity for the mu-opioid receptor over the kappa- and delta-opioid 
receptors (Table 11).   
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Table 11. Binding assay results for the 14-O-pyridinyl substituted naltrexone derivatives.  
 
Cmpd R μKi  
(nM) 
+/-   
SEM 
δKi  
(nM) 
+/-   
SEM 
κKi  
(nM) 
+/-   
SEM 
Ratio 
δ/μ 
Ratio 
κ/μ 
Comparison of 
Agonist Percent 
Stimulation to 
DAMGO 
Naltrexone  
 
0.260 +/- 0.017 117.058 +/- 8.945 5.150 +/- 0.264 450 8  
17 
N  
0.14 +/- 0.03 4610+/- 821 255 +/- 64.8 33650 1859 0.00 
18 
N
 
5.58 +/- 1.34 1144+/- 99.7 775 +/- 256 205 139 0.00 
19 
N  
1.59 +/- 0.61 1310 +/- 306 565+/- 109 55 355 0.00 
20 
 
The Ki values for the mu- and kappa-opioid receptors are n=3 and the Ki value for the delta-opioid receptor is n=2.  The 
averages are reported along with their standard error of the means (SEM) for each compound.  The comparison to percent 
stimulation of DAMGO is the Emax of the compound compared to the Emax of DAMGO using a [35S]GTPγS functional 
assay.  Note the abbreviations are Cmpd – compound; R – substituent; SEM - standard error of the mean. 
0.00 6 >81 729+/- 144 >10,000 123+/- 38.2 
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Based on the results, compound 17 was determined to be the lead compound for 
the first series of 14-O-pyridinyl substituted naltrexone derivatives.  Compound 17 has 
the highest affinity and selectivity for mu-opioid receptor compared to the other 
derivatives in the first series of 14-O-pyridinyl substituted naltrexone derivatives (Figure 
18).  Compared to naltrexone, 17 has comparable affinity to the mu-opioid receptor, but 
much higher selectivity for the mu-opioid receptor over the kappa- and delta-opioid 
receptors.  Compared to the control compound 20, it is clear that the nitrogen is necessary 
for higher binding affinity to the mu-opioid receptor.  Also, the GTPγS functional assay 
showed no agonist activity for the mu-opioid receptor for up to 10,000 nM of compound 
17.  
Lead Compound 17 of the 14-O -pyridinyl Naltrexone: 
Competition Binding Assay for Mu-, Delta- and Kappa-Opioid Receptors
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Figure 18. Competition binding curve for lead compound 17 for the mu-, delta-, and 
kappa-opioid receptors. 
 
 
 61
 Compound 18 displays high selectivity for the mu-opioid receptor over the delta- 
similar binding profile compared to compound 18.  It has 
 20 displays very low affinity to the mu-opioid receptor 
mpar
and kappa-opioid receptors.  When compared to naltrexone, 18 has one-tenth the affinity 
of naltrexone but is much more selective for mu- over kappa-opioid receptors.  Compared 
to the lead compound 17, 18 shows lower selectivity to the mu-opioid receptor.  Also, the 
GTPγS functional assay shows no agonist activity for the mu-opioid receptor for up to 
10,000 nM of compound 18.   
 Compound 19 shows a 
high affinity and selectivity for the mu-opioid receptor compared to the delta- and kappa-
opioid receptors.  However, it has about one-tenth the affinity to the mu-opioid receptor 
compared to naltrexone and compound 17.  Both compounds 18 and 19 have higher 
affinity to the mu-opioid receptor compared to the control 20 suggesting that the nitrogen 
may be playing an important role for binding to the mu-opioid receptor.  Additionally, the 
GTPγS functional assay shows negative results of the mu-opioid receptor for up to 
10,000 nM of compound 19.   
 The control compound
co ed to naltrexone (about one-hundredth the affinity) and to the other compounds in 
this series.  Therefore, the nitrogen atom in compounds 17 to 19 seems to play an 
important role in affinity and selectivity of these naltrexone derivatives to the mu-opioid 
receptor.     
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O-Quinolinyl and 14-O-Isoquinolinyl Substituted Naltrexone Derivatives 
 
pounds show that all of the compounds are 
4.2 14-
 The results for the second set of 14-O-heterocyclic substituted naltrexone
com more selective for the mu-opioid receptor 
over the kappa- and delta-opioid receptors (Table 12).  Also, these compounds have 
nanomolar level affinity for the mu-opioid receptor. 
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Table 12. Binding assay results for the 14-O-quinolinyl and 14-O-isoquinolinyl substituted naltrexone derivatives.   
 
Cmpd R μKi  
(nM)  
+/-   
SEM 
δKi  
(nM) 
+/-   
SEM 
κKi  
(nM) 
+/-   
SEM 
Ratio 
δ/μ 
Ratio 
κ/μ 
Comparison 
of Agonist 
Percent 
Stimulation to 
DAMGO 
Naltrexone  
 
0.260 +/- 0.017 117.058 +/- 8.945 5.150 +/- 0.264 450 8  
21 
N  
68.40 +/- 6.04  > 10,000 >10,000 >146 >147 0.00 
22 N
 
1.44 +/- 0.32 1362+/- 111 1377+/- 112 947 957 0.00 
23 
N  
2.60 +/- 0.72 2824+/- 14.6 665 +/- 98.2 901 247 22.0 +/- 10.3 
24 
 
The Ki values for the mu- and kappa-opioid receptor are n=3 and the Ki value for delta-opioid receptor is n=2.  The averages 
are reported along with their standard error of the mean (SEM) for each compound.  The comparison to percent stimulation of 
DAMGO is the Emax of the compound compared to the Emax of DAMGO using a [35S]GTPγS functional assay.   Note the 
abbreviations are Cmpd – compound; R – substituent; SEM - standard error of the mean. 
0.00 2 >44 474 +/- 176 > 10,000 225 +/- 46.6 
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 From the second series of naltrexone derivatives, 22 is determined to be the lead 
compound.  Compound 22 has lower affinity (about one-tenth) for the mu-opioid receptor 
compared to naltrexone, however it has much higher selectivity for the mu-opioid 
receptor over the kappa- and delta- opioid receptors.  Naltrexone has comparable affinity 
for the mu- and kappa-opioid receptors (Figure 19).  Compared to compound 24, 
compound 22 also shows much higher affinity and selectivity to the mu-opioid receptor.  
Therefore, the nitrogen plays an important role in the binding of these naltrexone 
derivatives to the mu-opioid receptor.  Additionally, compound 22 displayed no agonist 
activity for up to 10,000 nM concentration in the GTPγS functional assay.   
Lead Compound 22 of the 14-O -Quinolinyl Naltrexone: 
Competition Binding Assay for Mu-, Delta- and Kappa-Opioid Receptors
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Figure 19. Competition binding curve for lead compound 22 for the mu-, delta-, and 
kappa-opioid receptors. 
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 Compound 21 shows lower affinity to the mu-opioid receptor compared to 
naltrexone.  However, 21 still shows selectivity for the mu-opioid receptor over the delta- 
and kappa-opioid receptors.  Compared to the control 24, compound 21 has higher 
selectivity for the mu-opioid receptor compared to the delta- and kappa-opioid receptors.  
However, both compounds 21 and 24 display similar affinity to the mu-opioid receptor.  
The addition of the two-ring system may be too bulky to fit well in the binding pocket of 
the mu-opioid receptor, and this may explain the lower affinity seen with the quinoline 
series compared to the pyridine series.  Additionally, compound 21 displayed no agonist 
activity for up to 10,000 nM concentration in the GTPγS functional assay.   
 Compound 23 shows lower affinity to the mu-opioid receptor compared to 
naltrexone.  However, 23 displays selectivity for the mu-opioid receptor over the delta- 
and kappa-opioid receptors.  Compared to the lead compound 22, compound 23 shows 
similar affinity to the mu-opioid receptor.  Compared to the control 24, compound 23 has 
higher selectivity and affinity for the mu-opioid receptor compared to the delta- and 
kappa-opioid receptors.  Additionally, compound 23 displayed no agonist activity for up 
to 10,000 nM concentration in the GTPγS functional assay.   
 The control compound 24 shows low affinity to the mu-opioid receptor compared 
to naltrexone and to the other compounds in this series.  The nitrogen seems to play an 
important role in affinity and selectivity of these naltrexone derivatives to the mu-opioid 
receptor.  The decrease in affinity may be due to the addition of the second ring.  The 
substitution may be too bulky and may not be situated properly into the binding pocket.   
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4.3  Comparison between the Lead Compounds 17 and 22 
 Compound 17 and 22 are determined to be the lead compounds for the pyridinyl 
and quinolinyl series of the 14-O-heterocylic substituted naltrexone derivatives.  Both  
compounds contain a nitrogen atom next to the ester linkage.  The nitrogens in 
compounds 17 and 22 may arrange themselves in similar conformations in the binding 
pocket of the mu-opioid receptor.  Also, compound 17 has 10-times higher affinity for the 
mu-opioid receptor compared to compound 22.  This may be due to the addition of the 
second ring, making compound 22 more bulky. 
 Further in vitro studies need to be conducted on these two lead compounds such 
as a Schild regression analysis to determine their apparent affinities, or pA2, values for 
the mu-opioid receptor.  The Schild regression is used to determine the nature of 
antagonist either competitive or non-competitive.  Schild regression is used to compare 
the change in dose ratios, the ratio of the EC50 of an agonist alone compared to the EC50 
in the presence of an antagonist.  By altering the concentration of the antagonist, the dose 
ratio is altered.108
   Additionally, in vivo studies should be conducted to see how they act in the body 
and what kind of effects they produce in the body.  Finally, further optimization may be 
conducted in order to explore the possibility of an amide linkage over the ester linkage to 
the 14-position of naltrexone. 
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5. Molecular Modeling Study of the 14-O-Heterocyclic Substituted Naltrexone 
Derivatives in the Mu-Opioid Receptor 
 Molecular modeling studies have been conducted on the 14-O-heterocyclic 
substituted naltrexone derivatives, as well as naloxone and naltrexone, to gain insight on 
the interactions of the compounds in the binding pocket of the mu-opioid receptor.  A 
homology model of the mu-opioid receptor was built based on the X-ray crystal structure 
of the dark state of bovine rhodopsin (1U19; resolution of 2.2 Å).109  Clustal X was 
applied to align the sequences of human mu-, delta- and kappa-opioid receptors with 
bovine rhodopsin (Figure 20).110  Furthermore, the conserved residues found throughout 
most of the GPCRs were used to identify the helical regions of the opioid receptors and 
rhodopsin.109
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             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50         60                 
DOR_HUMAN    ---------- ---------- -MEPAPSAGA ELQPPLFANA SDAYPSAFPS AGANASGPPG  
MOR_HUMAN    MDSSAAPTNA SNCTDALAYS SCSPAPSPGS WVNLSHLDGN LSDPCGPNRT DLGGRDSLCP  
KOR_HUMAN    ---------- -MESPIQIFR GEPGPTCAPS ACLPPNSSAW FPGWAEPDSN GSAGSEDAQL  
Bov. Rhodo   ---------- ---------- ---------- ---MNGTEGP NFYVPFSNKT GVVRSPFEAP  
Clustal Co                                                     .  .             
 TM1 TM2 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                      70         80         90        100        110        120              
DOR_HUMAN    ARSASSLALA IAITALYSAV CAVGLLGNVL VMFGIVRYTK MKTATNIYIF NLALADALAT  
MOR_HUMAN    PTGSPSMITA ITIMALYSIV CVVGLFGNFL VMYVIVRYTK MKTATNIYIF NLALADALAT  
KOR_HUMAN    EPAHISPAIP VIITAVYSVV FVVGLVGNSL VMFVIIRYTK MKTATNIYIF NLALADALVT  
Bov. Rhodo   QYYLAEPWQF SMLAAYMFLL IMLGFPINFL TLYVTVQHKK LRTPLNYILL NLAVADLFMV  
Clustal Co        .       : *    :   :*:  * * .::  :::.* ::*. *  :: ***:** : .  
 TM3 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     130        140        150        160        170        180           
DOR_HUMAN    STLPFQSAKY LM-ETWPFGE LLCKAVLSID YYNMFTSIFT LTMMSVDRYI AVCHPVKALD  
MOR_HUMAN    STLPFQSVNY LM-GTWPFGT ILCKIVISID YYNMFTSIFT LCTMSVDRYI AVCHPVKALD  
KOR_HUMAN    TTMPFQSTVY LM-NSWPFGD VLCKIVISID YYNMFTSIFT LTMMSVDRYI AVCHPVKALD  
Bov. Rhodo   FGGFTTTLYT SLHGYFVFGP TGCNLEGFFA TLGGEIALWS LVVLAIERYV VVCKPMSNFR  
Clustal Co                   : **    *:    :    .   :::: *  ::::**: .**:*:. :   
 TM4
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     190        200        210        220        230        240           
DOR_HUMAN    FRTPAKAKLI NICIWVLASG VGVPIMV--M AVTRPRDGAV VCMLQFPSPS -WYWDTVTKI  
MOR_HUMAN    FRTPRNAKII NVCNWILSSA IGLPVMF--M ATTKYRQGSI DCTLTFSHPT -WYWENLLKI  
KOR_HUMAN    FRTPLKAKII NICIWLLSSS VGISAIVLGG TKVREDVDVI ECSLQFPDDD YSWWDLFMKI  
Bov. Rhodo   FG-ENHAIMG VAFTWVMALA CAAPPLVGWS RYIPEG-MQC SCGIDYYTPH EETNNESFVI  
Clustal Co   *    :* :      *::: .  . . :.                              :    *  
 TM5 TM6
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     250        260        270        280        290        300           
DOR_HUMAN    CVFLFAFVVP ILIITVCYGL MLLRLRSVRL LSG-SKEKDR SLRRITRMVL VVVGAFVVCW  
MOR_HUMAN    CVFIFAFIMP VLIITVCYGL MILRLKSVRM LSG-SKEKDR NLRRITRMVL VVVAVFIVCW  
KOR_HUMAN    CVFIFAFVIP VLIIIVCYTL MILRLKSVRL LSG-SREKDR NLRRITRLVL VVVAVFVVCW  
Bov. Rhodo   YMFVVHFIIP LIVIFFCYGQ LVFTVKEAAA QQQESATTQK AEKEVTRMVI IMVIAFLICW  
Clustal Co    :*:. *::* :::* .**   ::: ::..    .  *  .::   :.:**:*: ::* .*::**  
TM7 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     310        320        330        340        350        360           
DOR_HUMAN    APIHIFVIVW TLVDIDRRDP LVVAALHLCI ALGYANSSLN PVLYAFLDEN FKRCFRQLCR  
MOR_HUMAN    TPIHIYVIIK ALVTIP-ETT FQTVSWHFCI ALGYTNSCLN PVLYAFLDEN FKRCFREFCI  
KOR_HUMAN    TPIHIFILVE ALGSTS-HST AALSSYYFCI ALGYTNSSLN PILYAFLDEN FKRCFRDFCF  
Bov. Rhodo   LPYAGVAFYI FTHQGS---D FGPIFMTIPA FFAKTSAVYN PVIYIMMNKQ FRNCMVTTLC  
Clustal Co    *     :                     :    :. :.:  * *::* ::::: *:.*:       
 
 
             ....|....| ....|....| ....|....| ....|....| ....|. 
                     370        380        390        400               
DOR_HUMAN    KPCGRPDPSS FSRAREATAR ERVTACTPSD GPGGGAAA-- ------ 
MOR_HUMAN    PTSSNIEQQN STRIRQNTRD HPSTANTVDR TNHQLENLEA ETAPLP 
KOR_HUMAN    PLKMRMERQS TSRVRNTVQD PAYLRDIDGM NKPV------ ------ 
Bov. Rhodo   CGKNPLGDDE ASTTVSKTET SQVAPA---- ---------- ------ 
Clustal Co           ..  :   . .                                
 
Figure 20. Sequence alignment of the human mu-, delta-, and kappa-opioid receptors to 
bovine rhodopsin (1U19) using Clustal X.  The boxes represent the transmembrane (TM) 
regions.  The * represents conserved amino acid residues found among all GPCRs.  
Abbreviations: MOR=mu-opioid receptor, DOR=delta-opioid receptor, KOR=kappa-
opioid receptor, Bov. Rhodo=bovine rhodopsin. 
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First, the N and C termini of the mu-opioid receptor were cleaved off before Ile68 
and after Pro355 since the N and C termini have very low sequence homology among the 
three opioid receptors and bovine rhodopsin.  The helices of bovine rhodopsin were 
directly mutated with the residues of mu-opioid receptor.  Loop searches were conducted 
for the gaps found in EL2, EL3 and IL3 in order to maintain the conformation of the 
three-dimensional structure of the rhodopsin loops.  Since EL2 is important in the 
interaction of the opioids in the binding pocket, maintaining the conformation and 
integrity of EL2 was important.  Before minimization was conducted, side chain 
placement with a rotamer library (SCWRL) was used to check and fix improper 
positioning of the amino acid residues.111  The disulfide bond between cysteine residues 
130 of TM3 and 180 of EL2 was rejoined, and hydrogens were added and lone pairs were 
removed.  The receptor was minimized with Gasteiger-Hückel charges with a dielectric 
constant of 4.0 and 100,000 iterations.  Procheck was also performed to validate 
acceptable phi and psi angles in the protein and all of the residues were found to be in 
acceptable angle conformations. 
 Initial docking studies were conducted for the 14-O-heterocylic substituted 
naltrexone derivatives using GOLD 3.1.112  A distance constraint was set at 4Å between 
the positively charged nitrogen atom at the 17-position of naltrexone to the oxygen 
O1278 of the amino acid residue Asp149 of the mu-opioid receptor.  It turned out that the 
binding pocket is not large enough to incorporate the bulky heterocyclic side chain at the 
14-position of the naltrexone derivatives.  In order to accommodate the larger naltrexone 
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derivatives, compound 22 was interactively docked into the homology model of the mu-
opioid receptor. 
 Based on site-directed mutagenesis data, compound 22 was positioned in a similar 
manner as naltrexone.  First, the positively charged amino group at the 17-position of the 
compound was positioned between 3 to 4Å away from the amino acid residue Asp149 
since it has been shown to form a hydrogen bond with one of the oxygens of Asp149.87  
Next the phenol moiety at the 3-position of naltrexone and was placed about 3 to 4Å 
apart from the aromatic amino acid residues, Tyr212 and Phe223, of EL2.87  The amino 
acid residue Tyr150 of TM3 may also form a hydrogen bond with the phenol oxygen at 
the 3-position of the naltrexone backbone.88  The final hydrophobic interaction is 
between Leu221, Trp320 and Ile324 that can also interact with piperidinyl and 
cyclohexanoyl in naltrexone backbone.  Trp320 in EL3 was found to be critical in the 
binding of mu-opioid receptor.11  When Trp320 was mutated to leucine and lysine, the 
affinity of naltrexone significantly decreased in the mutated mu-opioid receptor.87,88 
 By satisfying these interactions, compound 22 was docked into the binding pocket 
and the receptor-ligand complex was minimized.  Compound 22 was used because it 
showed satisfactory binding affinity and selectivity for the mu-opioid receptor. After the 
minimization was complete, molecular dynamics simulation was conducted in Sybyl 7.1. 
The dynamics simulation was done in order to allow the formation of a larger 
binding pocket by moving amino acid residue side chains out of the binding pocket.  The 
dynamic simulations used Gasteiger-Hückel charges, a dielectric constant of 4.0, an 
aggregate with a 10Å radius around the ligand and a distance constraint of 4Å between 
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the positively charged amino group at the 17-position of naltrexone backbone to one of 
the oxygens of the amino acid residue Asp149 of the receptor.  Dynamic simulation 
involves the heating of the receptor, allowing the movement of side chains and stretching 
the binding cavity.  After the dynamics simulation the homology model of the mu-opioid 
receptor was minimized.  The final binding cavity was analyzed and the compound was 
removed (Figure 21). 
 
Figure 21. Binding pocket of the mu-opioid receptor with the critical amino acid 
residues. 
 
 
 The docking studies were conducted using GOLD 3.1 for each of the 14-O-
heterocyclic substituted naltrexone derivative and two mu-opioid receptor antagonists, 
naltrexone and naloxone, with the newly formed homology model of the mu-opioid 
receptor.112  Default settings were used in GOLD with a distance radius set to 10Å where 
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the central residues were set to oxygen O1278 of Asp149.  Also, a distance constraint of 
4Å was set between the 17-nitrogen atom of naltrexone with one of the oxygen O1278 of 
Asp149.  The GOLD scores for naltrexone and naloxone are 54.71 and 53.88, 
respectively.  The GOLD scores for the 17 to 20 derivatives range from 68.39 to 82.20 
and for the 21 to 24 derivatives range from 69.38 to 73.98.  The gold scores for all of the 
compounds are summarized in Table 13. 
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Table 13. Gold docking scores for opioid antagonists, naloxone and naltrexone, and 14-O-heterocyclic substituted naltrexone 
docked into the binding cavity of the homology model of the mu-opioid receptor.51   
 
Cmpd R Ki μ  
(nM) 
Gold 
Score 
S  
(hb_ext) 
S 
(vdw_ext) 
S  
(hb_int) 
S  
(int) 
S 
(con) 
Naltrexone 
 
 0.26 54.71 6.48 37.82 0.00 -3.77 -0.00 
Naloxone 
 
 1.90 53.88 6.48 37.17 0.00 -3.69 -0.00 
17 
N  
0.14 70.19 6.60 48.04 0.00 -2.47 -0.00 
18 N
 
5.58 69.38 5.83 48.88 0.00 -3.67 -0.00 
19 
N  
1.59 73.98 7.10 49.88 0.00 -1.70 -0.00 
20 
 
123 71.86 6.54 49.44 0.00 -2.66 -0.00 
21 N  
68.4 71.92 6.14 52.16 0.00 -5.93 -0.00 
22 
N
 
1.44 82.20 3.05 60.71 0.00 -4.33 -0.00 
23 
N  
2.69 68.89 6.73 53.92 0.00 -10.97 -0.00 
24 
 
225 68.39 6.28 55.45 0.00 -14.14 -0.00 
Abbreviations include Cmpd – Compound; R – substituent; S – Gold score component; hb – hydrogen bonding; vdw – Van der 
Waals interactions; ext – external interactions, int – internal interactions.  The score components for constraints indicates a 
negative score depending on the ability of the docking solution to meet the defined constraints. 
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 The docking scores do not seem to correlate well with the actual binding data 
obtained from the competition binding assays for the mu-opioid receptor.  First, naloxone 
and naltrexone are known opioid antagonist but are not selective for the mu-opioid 
receptor.  They both show similar selectivity for the mu- and kappa-opioid receptors.  
Their GOLD scores are the lowest among all of the compounds docked into the 
homology model of the mu-opioid receptor.  This may be due to the homology model 
being optimized with one of the 14-O-heterocyclic substituted naltrexone derivatives 
aligned in its binding pocket. 
 From the first series, pyridinyl series of compounds (17 to 20), the GOLD scores 
range from 69.38 to 73.98.  This may be due to the binding pocket of the homology 
model being explored around these naltrexone derivatives.  There is no significant 
difference in the GOLD scores between all four ligands.  However, there are some 
significant differences seen in their affinities for the mu-opioid receptor shown in the in 
vitro binding assays.  Therefore, the homology model does not display an accurate 
depiction of what is really occurring in the binding pocket.  These homology models are 
hypothetical pictures of how the compounds might bind.  
 From the second series, quinolinyl series of compounds (21 to 24), the GOLD 
scores range from 68.39 to 82.20.  This may be due to the binding pocket of the 
homology model being explored around these naltrexone derivatives.  Also, compound 
22 has the highest GOLD score of all the naltrexone derivatives showing that the binding 
pocket of the homology model was optimized with this compound.  Again, there is no 
significant difference in the GOLD scores between all four ligands.  But, there are some 
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significant differences seen in their affinities for the mu-opioid receptor shown in the in 
vitro binding assays.  Therefore, the homology model does not display an accurate 
depiction of what is really occurring in the binding pocket.  These homology models are 
hypothetical pictures of how the compounds might bind.  
 The docking solutions for several of these compounds including the two lead 
compounds, 17 and 22, as well as naloxone and naltrexone are shown in figures 22 to 24. 
O
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Figure 22. Lead compound 17 best ranked docking solution in the binding cavity of the 
mu-opioid receptor homology model. 
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Figure 23. Compound 22, highest Gold score of all derivatives, best ranked docking 
solution in the binding cavity of the mu-opioid receptor homology model. 
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Figure 24. Opioid antagonists naltrexone (purple) and naloxone (yellow) best ranked 
docking solutions in the binding cavity of the mu-opioid receptor homology model.   
 
 
 In the homology model of the mu-opioid receptor binding pocket, naloxone and 
naltrexone seem to be overlapping each other (Figure 24).  Compared to the lead 
compound, 17, of the 14-O-heterocyclic substituted naltrexone derivatives, naltrexone is 
not interacting with the amino acid residue Trp320, which seems to interact with the 
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pyridine substituent on the lead compound, 17 (Figure 25).  This may help explain the 
high Van der Waals contributions for the 14-O-heterocyclic substituted naltrexone 
derivatives and the lower GOLD scores of naloxone and naltrexone.  Also, the poor 
correlation seen between the affinities of the 14-O-heterocylic substituted naltrexone 
derivatives and the GOLD score values may be due to the small sample size. 
 
 
Figure 25. Opioid antagonist naltrexone (purple) and lead compound 17 (green) best 
ranked docking solutions in the binding cavity of the mu-opioid receptor homology 
model.   
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6. Competition Binding Assay Results for the 6-N-heterocyclic Substituted 
Naltrexamine  Derivatives 
 Two different sets of 6-N-heterocyclic substituted naltrexamine derivatives were 
designed (see Figure 16 on page 30).  The first set carries a pyridinyl ring and the second 
set carries a quinolinyl or isoquinolinyl ring.  Also, the α and β configurations at the 6-
position of the naltrexone were investigated to determine if stereochemical arrangement 
altered their affinities towards the mu-opioid receptor.   
 A hetero-aromatic moiety was introduced to the 6-position of naltrexamine in 
order to design selective mu-opioid antagonists.  An amide bond was used as the linkage 
of the side chain moiety to the skeleton of naltrexamine.  Both the α and β stereochemical 
configurations of these compounds were synthesized to determine if stereochemical 
arrangement plays an important role in affinity and selectivity for the mu-opioid receptor.  
The nitrogen in the aromatic system acts as a hydrogen bond acceptor to probe the 
possibility of hydrogen bond formation with amino acid residues Tyr210 or Trp318.  
Control compounds with phenyl and naphthalene rings were also designed and 
synthesized as control compounds to test the hydrogen bonding hypothesis. 
 
6.1 6-N-Pyridinyl Substituted Naltrexamine Derivatives 
 The first set of compounds, 6-N-pyridinyl substituted naltrexamine derivatives, all 
show nanomolar to subnanomolar affinity for the mu-opioid receptor (Table 14).  
Stereochemical arrangements did not seem to be a major factor in the determination of 
affinity and selectivity of these compounds for the mu-opioid receptor.  The controls, 31 
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and 32, display little selectivity between the mu- and kappa-opioid receptors.  This 
suggests that the nitrogen in the substitution may play an important role in the binding of 
these naltrexamine derivatives.  
 From the pyridinyl series of compounds, compound 26 is determined to be a lead 
compound (Figure 26).  Compound 26 has similar binding affinity to the mu-opioid 
receptor compared to naltrexone.  However, 26 is much more selective to the mu-opioid 
receptor compared with naltrexone.  Compound 26 has higher selectivity to the mu-
opioid receptor compared to the control compound 32.  However, control compound 31 
seems to have similar binding and selectivity characteristics as compound 26.  
Additionally, the GTPγS functional assay was conducted and the Emax of compound 26 
was compared with the Emax of DAMGO.  From these results, it seems that compound 
26 acts as a partial opioid antagonist to the mu-opioid receptor compared with DAMGO.  
However, the control compound 31 also seems to act as a partial antagonist for the mu-
opioid receptor, while compound 31 shows higher agonist activity compared with 
compound 26.  
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Figure 26. Competition binding curve for lead compound 26 for the mu-, delta-, and 
kappa-opioid receptors. 
 
Lead Compound 26 of the 6-N -Pyridinyl Naltrexamine: 
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Table 14. Binding assay results for the 6-N-pyridinyl substituted naltrexamine derivatives.   
 
Cmpd 6-
Config. 
6-N  
R 
μKi  
(nM)  
+/-   
SEM 
δKi  
(nM) 
+/-   
SEM 
κKi  
(nM) 
+/-   
SEM 
Ratio 
δ/μ 
Ratio 
κ/μ 
Comparison of Agonist 
Percent Stimulation to 
DAMGO 
Naltrexone  
 
 0.260 +/- 0.017 117.058 +/- 8.945 5.150 +/- 0.264 450 8  
25 α 0.16 +/- 0.08 450 +/- 92.6 85.2 +/- 24.8 2728 517 44.82 +/- 4.50 
26 β N  
 
0.15 +/- 0.04 3667 +/- 34.8 5.98 +/- 1.30 24779 40 29.11 +/- 5.00 
27 α 0.59 +/- 0.11 2060 +/- 354 21.6 +/- 10.0 3515 37 37.32 +/- 4.87 
28 β 
N
 
 
0.41 +/- 0.08 3063 +/- 87.7 59.5 +/- 8.31 7398 144 22.72 +/- 0.84 
29 α 2.79 +/- 0.44 678 +/- 168 234 +/- 12.6 243 84 37.79 +/- 2.68 
30 β N  
 
6.46 +/- 1.56 2375 +/- 232 307 +/- 74.8 367 47 41.09 +/- 4.32 
31 
(Control) 
α 0.13 +/- 0.04 443 +/- 56.4 46.0 +/- 6.68 3464 359 41.24 +/- 7.48 
32 
(Control) 
β 
The Ki values for the mu- and kappa-opioid receptor are n=3 and the Ki value for the delta-opioid receptor is n=2.  The 
averages are reported along with their standard error of the means (SEM) for each compound.  The comparison to percent 
stimulation of DAMGO is the Emax of the compound compared to the Emax of DAMGO using a [35S]GTPγS functional 
assay.  Note the abbreviations are Cmpd – compound; R – substituent; SEM  - standard error of the mean; Config – 
configuration. 
67.29 +/- 3.96 8 801 8.75 +/- 1.72 820 +/- 57.6 1.02 +/- 0.34 
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 Another type of [35S]GTPγS functional assay was conducted to determine if these 
compounds are antagonists and the amount of antagonism they produce.  Therefore, an 
assay was conducted to generate a dose-response curve of DAMGO, a mu-opioid 
receptor agonist, with and without the naltrexamine derivatives.  An antagonist is 
supposed to produce a right shift in the curve and the shift in the curve is measured to 
demonstrate the relative antagonist activity of the compound.   
 To further characterize compound 26, a functional assay was conducted to 
determine whether or not it displays antagonistic effects on the interaction of DAMGO 
with the mu-opioid receptor.  Compound 26 produces a right shift in the stimulation 
curve produced by DAMGO activation of the receptor (Figure 27).  The EC50 and Emax 
for DAMGO alone is 68.3 nM and 424.66% stimulation, respectively.  The addition of 
7.5 nM of compound 26, about 30-times the IC50 (0.26 nM) of compound 26, alters the 
EC50 and Emax for DAMGO to 118.0 nM and 408.48% stimulation, respectively.  There 
is a 2-fold increase in the EC50 and a slight almost negligible decrease in the stimulation 
of [35S]GTPγS.  The dissociation constant, or Ke, for compound 26 is 16.089 +/- 8.640 
nM.  The reported dissociation constant or Ke for naltrexone is 0.33 nM.113  In order to 
make a better comparison with naltrexone, a pA2 value needs to be determined using a 
Schild regression analysis with varying concentrations of antagonist.  The pA2 value for 
naltrexone is reported to be about 8.9 when given intravenously to rats given DAMGO.114   
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Lead Compound 26 of 6-N-Pyridinyl Substituted Naltrexamine: 
[35S]GTPγS Agonist Binding Assay Effects on the Binding of  DAMGO at the Mu-Opioid Receptor
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Figure 27. Stimulation of [35S]GTPγS by DAMGO and the effects of 26 on the 
stimulation produced by DAMGO at the mu-opioid receptor.  The concentration of 26 
used in this assay is 7.5 nM.  The averages of the data was produced from an n=2. 
 
 
6.2 6-N-quinolinyl and 6-N-isoquinolinyl Substituted Naltrexamine Derivatives 
The second set of compounds, 6-N-quinolinyl and 6-N-isoquinolinyl substituted 
(Table 15).  Stereochemical arrangements did not seem to be a major factor in the 
The control compound 42, displays no selectivity between all three opioid receptors, 
while control compound 41 shows some selectivity to the mu-opioid receptor compared 
mu-opioid receptor compared to naltrexone and the other heterocyclic compounds in this 
naltrexamine derivatives, subnanomolar to nanomolar affinity to the mu-opioid receptors 
determination of affinity and selectivity of these compounds for the mu-opioid receptor.  
to the delta- and kappa-opioid receptor.  However, it also displays lower affinity to the 
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titution may play an important role in the 
binding of these naltrexone derivatives. 
series.  The control compounds display a decrease in affinity to the mu-opioid receptor 
and may suggest that the nitrogen in the subs
86 
 
Table 15. Binding assay results for the 6-N-quinolinyl and 6-N-isoquinoline substituted naltrexamine derivatives.   
 
Cmpd Config. 6-N 
R 
μKi  
(nM)  
+/-   
SEM 
δKi  
(nM) 
+/-   
SEM 
κKi  
(nM) 
+/-   
SEM 
Ratio 
δ/μ 
Ratio 
κ/μ 
Comparison of Agonist 
Percent Stimulation to 
DAMGO  
Naltrexone  
 
 0.260 +/- 0.017 117.058 +/- 8.945 5.150 +/- 0.264 450 8  
33 α 
 
0.23 +/- 0.12 2161+/- 125 10.6 +/- 1.03 9398 46 40.9 +/- 7.20 
34 β 
 
N
 0.10 +/- 0.03 186 +/- 2.58 5.14 +/- 1.33 1775 49 65.4 +/- 6.13 
35 α 
 
0.56 +/- 0.15 1108 +/- 103 26.9 +/- 5.32 1997 49 15.8 +/- 2.53 
36 β 
 
N  0.11 +/- 0.04 578 +/-  5.28 1.75 +/- 0.76 5349 16 33.0 +/- 2.46 
37 α 
 
0.13 +/- 0.03 360 +/- 11.3 2.00 +/- 0.12 2791 15 44.8 +/- 3.96 
38 β 
 
N  0.08 +/- 0.02 125 +/- 32.3 0.62 +/- 0.22 1527 8 53.4 +/- 8.74 
39 
 
α 
 
0.71 +/- 0.27 338 +/- 54.2 6.84 +/-  2.62 473 10 75.7 +/- 17.8 
40 β 
 
N
N
 0.14 +/- 0.04 352.8 +/- 10.6 1.29 +/- 0.23 2613 10 53.0 +/- 6.75 
41 
(Control) 
α 
 
8.78 +/- 1.80 861 +/- 168 641 +/- 166 98 73 72.8 +/- 6.07 
42 
(Control) 
β 
 
11.9 +/- 0.69 
The Ki values for the mu- and kappa-opioid receptor are n=3 and the Ki value for delta-opioid receptor is n=2.  The averages 
are reported along with their standard error of the means (SEM) for each compound.  The comparison to percent stimulation of 
DAMGO is the Emax of the compound compared to the Emax of DAMGO using a [35S]GTPγS functional assay.  Note the 
abbreviations are Cmpd – compound; R – substituent; SEM  - standard error of the mean; Config - configuration.  
1 0.52 67.3 +/- 17.8 30.2 +/- 4.80 57.4 +/- 0.26  
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 From the second series of compounds, compound 35 is determined to be a lead 
compound to undergo further optimization.  Compound 35 has comparable affinity with 
naltrexone to the mu-opioid receptor.  However, this compound displays higher 
selectivity for the mu-opioid receptor over the delta- and kappa-opioid receptors not seen 
with naltrexone (Figure 28).  Compared to the control compounds 41 and 42, compound 
35 displays both higher selectivity and affinity to the mu-opioid receptor suggesting that 
the nitrogen may play an important role in its binding to the mu-opioid receptor.  Also, 
the GTPγS functional assay was conducted and the Emax value of compound 35 was 
compared with the Emax of DAMGO.  From these results, it seems that compound 35 
acts as a partial opioid antagonist to the mu-opioid receptor compared with DAMGO.  
However, the control compound 42 also seems to act as a partial antagonist for the mu-
opioid receptor.   
Lead Compound 35 of the 6-N -Isoquinoline Substituted Naltrexamine: 
Competition Binding Assay for Mu-, Delta- and Kappa-Opioid Receptors
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Figure 28. Competition binding curve for lead compound 35 for the mu-, delta-, and 
kappa-opioid receptors. 
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To further characterize compound 35, a functional assay was conducted to 
determine whether or not it displays antagonistic effects on the interaction of DAMGO 
with the mu-opioid receptor.  Stimulation of [35S]GTPγS through binding of an agonist 
produces a sigmoidal concentration effect curve.  Compound 35 produced a right shift in 
the stimulation of mu-opioid receptor by DAMGO (Figure 29).  The EC50 and Emax for 
DAMGO alone are 57.1 nM and 243.83% stimulation, respectively.  The addition of 20.0 
nM of naltrexamine derivative 35, about 20-times the IC50 (1.00 nM), altered the EC50 
and Emax for DAMGO to 73.5 nM and 221.45% stimulation, respectively.  A 1.2-fold 
increase was seen in the EC50 and a slight almost negligible decrease in the stimulation of 
[35S]GTPγS.  The dissociation constant, or Ke, for compound 35 is 74.204 +/- 5.260 nM 
and only a 1.2-fold shift increase was observed with a 20.0 nM concentration of 
compound 35.  A Schild regression analysis needs to be conducted where concentration-
effect curves are constructed in the presence of increasing concentrations of antagonist in 
order to determine the apparent affinity, pA2, for compound 35. 
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Lead Compound 35 of 6-N -Isoquinoline Substituted Naltrexamine: 
[35S]GTPγS Agonist Binding Assay Effects on the Binding of  DAMGO at the Mu-
Opioid Receptor
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Figure 29. Stimulation of [35S]GTPγS by DAMGO and the effects of 35 on the 
stimulation produced by DAMGO at the mu-opioid receptor.  The concentration of 35 
used in this assay is 20.0 nM.  The averages of the data was produced from an n=2. 
 
6.3 Comparison of the Lead Compounds 26 and 35 
 From the 6-N-heterocyclic substituted naltrexamine derivatives, two lead 
compounds were identified: 26 and 35.  In order to further characterize the antagonistic 
profile of these two compounds, a Schild regression analysis needs to be conducted with 
varying concentrations of the compounds in order to determine and compare their 
apparent affinities, pA2 values.  The two different configurations, α and β, shows no 
difference in their affinities towards the mu-opioid receptors.  This may be explained by 
their three-dimensional structure between the α-configuration (33) and β-configuration 
(34) of the 6-N-heterocyclic substituted naltrexamine derivatives (Figure 30).  The lead 
compounds can be further optimized by the addition of a third phenyl ring to compound 
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35 in order to see if the increase in bulk is tolerated at this position.  Compounds 39 and 
40 have two nitrogen atoms in the quinoline ring and demonstrate partial agonist activity 
around 52.95% and 75.69% for the α and β configurations, respectively.  Therefore, the 
addition of the second nitrogen atom showed no enhancement of affinity or antagonism. 
 
 
Figure 30. Overlay of the three-dimensional configurations of compounds 33 (left) and 
34 (right).   
 
 
 
  
V. Conclusions 
 
 
 Currently there are many opioid agonists available for clinical use as analgesics 
that act in the centeral nervous system through the opioid receptors.  There are three main 
opioid receptors, including the mu-, delta-, and kappa-opioid receptors.  However, many 
of these agonists have been associated with notorious side effects including respiratory 
depression, tolerance and dependence.  Morphine is the most commonly used opioid 
agonist in the treatment of chronic and post-operation pain.  However, morphine is highly 
addictive both physically and psychologically.2  It has been shown that the analgesic and 
adverse effects of morphine are due to its interactions with the mu-opioid receptor.  
Therefore, the characterization of the mu-opioid receptor is essential for understanding 
the addictive and analgesic actions of morphine. 
 The addiction and dependency of these opioid receptor agonists can be treated 
through detoxification or drug replacement therapy, including the application of opioid 
antagonists.  Opioid antagonists also play important roles in the pharmacological study of 
opioid receptors.  Due to the role of the mu-opioid receptor in analgesia and drug 
addiction, a highly selective mu-opioid receptor antagonist will be useful as a 
pharmacological tool in the study of the structure-activity relationships of mu-opioid 
receptors.
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 Naltrexone is a non-peptide mu-opioid receptor antagonist. It also is a long-acting 
and reversible opioid ligand in the treatment of opioid dependence and many other 
addictions.  Although naltrexone has the ability to promote abstinence and prevent 
relapse, it also has many side effects due to its low selectivity to the opioid receptors.6,9  
On the other hand, CTAP and CTOP, two representative mu-opioid receptor selective 
peptidyl antagonists, are available but may undergo metabolic inactivation faster than the 
non-peptidyl opioid antagonists.  Therefore, the development of selective non-peptidyl 
mu-opioid receptor antagonists is necessary to help alleviate any adverse effects seen by 
opioid antagonists with low selectivity. 
   Besides the antagonists being selective for the mu-opioid receptor, these 
compounds also need to be reversible.  Irreversible antagonists will bind covalently to the 
receptor and inactivate the receptor indefinetly.  Reversible antagonists would be 
preferred since they temporarily “knock-out” the receptors during pharmacological 
studies and can be washed out from the binding locus to revive the receptors. 
 This project involved the design of reversible and selective non-peptidyl mu-
opioid receptor antagonists.  Since naltrexone has high affinity to the mu-opioid receptor, 
it is an ideal template for the development of these antagonists.  The molecular design of 
these antagonists was based on the identification of important pharmacophore elements 
found in several known opioid agonists and antagonists.  By applying the “message-
address” concept and comparative conformational studies, the major pharmacophore 
elements were identified in previous studies.  From this study it was suggested that 
agonists and antagonists may share a similar “address” component that confers their 
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selectivity to the mu-opioid receptor while the “message” component is different due to 
opposite signal transductions. 
 Site-directed mutagenisis and molecular modeling studies have shown that certain 
amino acid residues are critical for ligand selectivity. Amino acid residues that comprise 
an aromatic binding pocket include Tyr210, Phe313, and Trp318 located in extracellular 
loops (EL) 2 and 3 are not conserved in the delta- and kappa-opioid receptors.  Therefore, 
similar aromatic binding pockets may not exisit in the delta- and kappa-opioid receptors.  
More importantaly, Trp318 is a significant contributor to the selectivity of the mu-opioid 
receptor agonists and antagonists.88
Based on previous studies conducted in Dr. Zhang’s laboratory, it was determined 
that a mu-opioid receptor antagonist with an aromatic structural feature may interact with 
EL3 and lead to higher selectivity to the mu-opioid receptor.  Therefore, the specific 
hypothesis for this study was that a mu-opioid receptor antagonist with an aromatic 
structural feature may interact with EL3 and lead to higher selectivity to the mu-opioid 
receptor.  A series of new ligands that satisfy the requirements of the mu-opioid receptor 
binding pocket were designed and synthesized to test their affinity towards the mu-, 
delta- and kappa-opioid receptors.    
Two novel series of selective non-peptidyl mu-opioid receptor antagonists were 
developed.  The first series are 14-O-heterocylic substituted naltrexone derivatives that 
were designed by the addition of hetero-aromatic moieties including pyridine, quinoline 
and isoquinoline moieties attached to the 14-position of naltrexone through an ester 
linkage.  The addition of the hetero-aromatic to the 14-position of naltrexone may 
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provide essential hydrogen bonding to interact with Trp318 in the aromatic binding 
pocket in the mu-opioid receptor and confer higher selectivity to the mu-opioid receptor. 
The second series of selective non-peptidyl mu-opioid receptor antagonists were 
6-N-heterocylic substituted naltrexamines.  These antagonists contain a heterocyclic 
moiety including pyridine, quinoline, and isoquinoline linked at the 6-position of 
naltrexamine through an amide bond.  The aromatic character of the heterocylic moiety 
may help provide hydrogen bonding interaction with the aromatic binding pocket in the 
mu-opioid receptor.  Also the α and β stereochemical arrangements were tested to 
determine if they play a role in selectivity to the mu-opioid receptor. 
Finally, for both series of compounds, phenyl and napthalenyl compounds were 
used as controls to test the hypothesis that the addition of heterocyclic moieties to 
naltrexone and naltrexamine’s backbone will provide hydrogen bonding with Trp318 in 
EL3 of the binding pocket of the mu-opioid receptor.  Chemical synthesis of the 14-O-
heterocylic substituted naltrexone derivatives was conducted in a “one-pot” reaction 
condition by the direct coupling of the heterocyclic moiety to the 3- and 14-positions of 
naltrecxone.  This is followed by the selective removal of the heterocylic moiety at the 3-
position of naltrexone.  Finally these compounds were converted into dihydrochloride 
salts except for compound 21.  Although most compounds were synthesized easily in the 
above manner, some difficulty was encountered in the synthesis of compounds 17, 20 and 
24.  
Following chemical synthesis of the selective non-peptidyl mu-opioid receptor 
antagonist, biological evaluation was conducted to determine the affinity and selectivity 
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of these compounds for the mu-, delta-, and kappa-opioid receptors.  Besides the test of 
their affinities, these compounds were also characterized for their potential agonist 
activity using a functional [35S]GTPγS assay. 
For the first series of compounds, the 14-O-heterocylcic substituted naltrexone 
derivatives, all of these compounds, except for the controls, displayed higher selectivity 
for the mu-opioid receptor compared to the delta- and kappa-opioid receptors.  
Additionally, all of the compounds displayed an antagonist activity profile.  Compounds 
17 and 22 were identified as lead compounds with comparable affinity with naltrexone 
for the mu-opioid receptor but much higher selectivity for the mu-opioid receptor over 
the kappa- and delta-opioid receptors.  Although compound 17 has similar affinity to the 
mu-opioid receptor compared to naltrexone but it has much higher selectivity to the mu-
opioid receptor compared to naltrexone.  Compound 22 also carries higher selectivity to 
the mu-opioid receptor compared to naltrexone though its binding affinity is about ten 
times lower than that of naltrexone. 
The second series of compounds, 6-N-heterocylcic substituted naltrexamine 
derivatives, display similar affinity and selectivity compared to the 14-O-heterocylcic 
substituted naltrexone derivatives.  Compounds 26 and 35 have been identified as a lead 
compound with a 10-fold decrease in affinity compared with naltrexone for the mu-
opioid receptor but higher selectivity, about 40- and 49-fold respectively, for the mu-
opioid receptor over the kappa-opioid receptors.  DAMGO, a full mu-opioid receptor 
agonist, has been used to compare and determine agonistic characteristics of all of the 
compounds.  All of the compounds are partial mu-opioid receptor agonists while the lead 
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compounds 26 and 35 have about 29.11% and 15.83% agonist activity compared to 
DAMGO, respectively.  
For both series of compounds it is important to note that the controls which lacks 
an heterocyclic moiety to provide hydrogen bonding with EL3 for the mu-opioid receptor 
also showed much lower selectivity to the mu-opioid receptor.  Therefore, it is clear that 
the nitrogen in the aromatic moieties is necessary for higher binding affinity to the mu-
opioid receptor compared to the delta- and kappa-opioid receptors. 
In order to get a better understanding of how these compounds are binding to the 
mu-opioid receptor, a homology modeling study of the mu-opioid receptor was 
conducted.  The homology model of the mu-opioid receptor was built using the crystal 
structure of the dark state bovine rhodopsin as the template.  Docking simulations of each 
ligand in the homology model of the mu-opioid receptor were then conducted and Gold 
scores were determined for each ligand.  The Gold docking scores did not correlate very 
well with the affinities determined in the biological evaluation studies.  The lead 
compound 22 displayed the highest Gold score of all of these derivatives.  Lead 
compound 17 also displays a high Gold score.  Naltrexone showed one of the lowest 
Gold docking scores compared to the designed compounds and may be due to the weaker 
interaction of naltrexone in the binding pocket. 
 In summary, from the first series of 14-O-heterocylcic substituted naltrexone 
derivatives, compounds 17 and 22 were determined to be the lead compounds using both 
competition binding assays for all three opioid receptors and functional assays to 
determine their agonist activity profile.  Although compounds 14-O-heterocylcic 
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substituted naltrexone derivatives 17 and 22 display similar or lower affinity to the mu-
opioid receptor compared to naltrexone, they both displayed much higher selectivity.  
From the second series of 6-N-heterocylic substituted naltrexamine derivatives, two lead 
compounds were identified, 26 and 38.  Both of these compounds have high selectivity 
and affinity to the mu-opioid receptor.  Both of these compounds also display partial 
agonist activity a the mu-opioid receptor compared to DAMGO in the [35S]GTPγS 
functional binding assay.  Further optimization of these lead compounds may lead us to a 
potent and highly selective mu-opioid receptor antagonist with diminished agonist 
activity. 
 
 
 
 VI. Experimental 
 
1. Chemical Synthesis of 14-O-Heterocyclic Substituted Naltrexone Derivatives 
 Two synthetic routes are applied to synthesize the 14-O-heterocyclic substituted 
naltrexone derivatives.  The first synthetic route is adapted when the starting material is 
an acyl chloride while the second is for the starting material as a carboxylic acid.92,93  All 
compounds are characterized by 1H-NMR, 13C-NMR, MS and IR.  Melting points are 
determined by Fischer Scientific melting point apparatus.  The 1H-NMR (300 MHz) and 
13C-NMR (75 MHz) spectra are obtained on a Varian Gemini spectrometer and 
tetramethylsilane is used as the internal standard.  Mass spectrometer spectra are obtained 
using direct-infusion ESI-MS-MS.  Samples are diluted 1:100 with methanol and 
introduced into a Quattro II triple quadruple mass spectrometer with an electrospray ion 
source (Micromass, Altrincham, England) at a flow rate of 10 mL/min using a Harvard 
Apparatus Syringe Pump model 11 (Holliston, MA).  The samples are analyzed in 
negative ion mode with a capillary voltage of 2.3 kV, cone 30V, and extractor 5V.  IR 
spectra are obtained using a Nicolet 5ZDX FT-IR spectrometer with potassium bromide 
as the background.  Column chromatography is performed by using silica gel (grade 60 
mesh; Bodman Industries, Ashton, PA).  Routine thin-layer chromatography (TLC) is 
performed on silica gel GHIF plates (250 μ, 2.5 x 10 cm, Analtech Inc. Newark, DE).  All
98 
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 the compounds are converted to salts with 2.2 equivalents of 1.25 molar hydrogen 
chloride acid in methanol (Fluka).                  
 
1.1 Synthetic Route A: Acyl Chloride 
 One equivalent of naltrexone (NTX) is dissolved in 5 mL of DMF.  Then 2.2 
equivalents of the acyl chloride and 4.4 equivalents of TEA are added. The reaction 
mixture is heated at reflux for 4 h under N2 atmosphere.  The reaction mixture is then 
cooled down and TLC is conducted to monitor the reaction (40:1:0.01 
CH2Cl2:MeOH:NH3H2O).  
 The reaction mixture is transferred to a large round bottom flask; 20 mL of 4% 
H2SO4 and 20 mL of MeOH are added to the mixture and stirred for 4 h at room 
temperature.  TLC is taken again to monitor the reaction.  The reaction mixture is 
neutralized by adding a dilute solution of ammonium hydroxide in a dropwise manner 
until it reached a pH of 7.  The solvents are evaporated under reduced pressure and the 
residue is purified by column chromatography (50:1:0.04 CH2Cl2:MeOH:NH3H2O).  The 
final compound is converted into a hydrochloride salt and stored in the freezer. 
  
1.2 Synthetic Route B: Carboxylic Acids 
 In order to convert the carboxylic acid to an acyl chloride, the carboxylic acid is 
dried using a vacuum pump and toluene is dried overnight under 4Å molecular sieves.  
An excess amount of thionyl chloride (SOCl2) is added to the carboxylic acid and then 
heated at reflux continuously under N2 atmosphere for 3 h.  The reaction mixture is then 
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immediately distilled under N2 atmosphere by the addition and distillation of dried 
toluene three times to remove all of the excess SOCl2.  
 One equivalent of pre-dried NTX is added to the reaction mixture containing the 
acyl chloride and dissolved in 5 mL of DMF.  Then 4.4 equivalents of TEA is added to 
the reaction mixture.  The reaction mixture is heated at reflux at for 4 h under N2 
atmosphere.  The reaction mixture is then cooled down and TLC was conducted to 
monitor the reaction (40:1:0.1 CH2Cl2:MeOH:NH3H2O). 
 Next, the reaction mixture is transferred to a large round bottom flask.  Then 20 
mL of 4% H2SO4 and 20 mL of MeOH are added to the reaction mixture and stirred for 4 
h at room temperature.  TLC is taken again to monitor the reaction.  The reaction mixture 
is neutralized by adding a dilute solution of ammonium hydroxide in a dropwise manner 
till it reached a pH of 7.  The solvents are evaporated under reduced pressure and the 
residue is purified by column chromatography (50:1:0.04 CH2Cl2:MeOH:NH3H2O).  The 
final compound is converted to a hydrochloride salt and stored in the freezer. 
 
2. Final Compounds  
17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(pyridinyl-
2’carboxy)morphinan-6-one (17)     
Following procedure B, picolinic acid (492 mg, 4.0 mmol), SOCl2 (5 mL), DMF (5 mL), 
naltrexone (341 mg, 1.0 mmol) and TEA (1.12 mL, 809 mg, 8.0 mmol), are applied.  The 
reaction mixture is heated at reflux overnight under a nitrogen atmosphere.  A black 
residue is obtained and purified by column chromatography (200:1:0.04 and 100:1:0.04 
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CH2Cl2:MeOH:NH3H2O) system and 225 mg (50.0% yield) of a red oil is isolated and 
converted to hydrochloride salt.  1H-NMR (300 MHz, CDCl3) (free base) δ 0.58 (m, 4H), 
1.12 (m, 1H), 1.91 (m, 2H), 2.47 (m, 2H), 2.72 (m, 2H), 3.09 (m, 2H), 3.15 (m, 2H), 3.21 
(m, 2H), 3.36 (m, 1H), 3.50 (b, 1H, D2O exchangeable), 4.68 (m, 1H), 6.61 (d, J=8.1 Hz, 
1H), 6.74 (d, J=8.1 Hz, 1H), 7.27 (m, 1H), 7.63 (m, 1H), 7.80 (m, 1H), 8.60 (m, 1H); 1H-
NMR (300 MHz, CD3OD) (dihydrochloride salt) δ 0.86 (m, 4H), 1.25 (m, 1H), 1.35 (m, 
1H), 1.72 (b, 1H, D2O exchangeable), 2.10 (b, 1H, D2O exchangeable), 2.28 (m, 2H), 
2.32 (m, 2H), 2.84 (m, 2H), 3.05 (m, 2H), 3.21 (m, 2H), 3.33 (m, 1H), 4.11 (m, 1H), 4.89 
(b, 1H, D2O exchangeable), 6.67 (d, J=6.6 Hz, 1H), 6.75 (d, J=6.6 Hz, 1H), 8.18 (m, 1H), 
8.23 (m, 1H), 8.70 (m, 1H), 8.96 (m, 1H); 13C-NMR (75 MHz, CD3OD) (dihydrochloride 
salt) δ 1.56, 4.34, 4.97, 22.49, 26.90, 27.89, 29.30, 30.23, 34.17, 37.51, 52.99, 56.92, 
61.69, 69.52, 88.54, 117.95, 119.98, 125.40, 127.39, 129.90, 138.89, 139.87, 142.36, 
146.38, 161.31, 207.59; IR (cm-1) 794.26, 1259.60, 1660.32, 3411.85; MS m/z (relative 
intensity, ion): 447.0 (100%, (M+H)+). 
 
17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(pyridinyl-
4’carboxy)morphinan-6-one (18) 
Following procedure A, isonicotinyl chloride (534 mg, 3.0 mmol, 3 equivalents), 
naltrexone (341 mg, 1.0 mmol), DMF (5 mL), and TEA (0.84 mL, 607 mg, 6.0 mmol, 6 
equivalents), are applied.  Product is isolated by column chromatography (60:1:0.04 
CH2Cl2:MeOH:NH3H2O) and 310 mg (69.0% yield) of a bright yellow powder is 
obtained and converted to hydrochloride salt.  mp 190-195 °C;  1H-NMR (300 MHz, 
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CDCl3) (free base) δ 0.58 (m, 4H), 0.89 (m, 1H), 1.66 (m, 2H), 1.93 (m, 2H), 2.18 (m, 
2H), 2.46 (m, 2H), 2.74 (m, 2H), 3.03 (m, 2H), 3.95 (m, 1H), 4.73 (b, 1H, D2O 
exchangeable), 5.30 (m, 1H), 6.75 (d, J=8.1 Hz, 1H), 6.96 (d, J=8.1 Hz, 1H), 8.02 (m, 
2H), 8.84 (m, 2H); 1H-NMR (300 MHz, CD3OD) (dihydrochloride salt) δ 0.82 (m, 4H), 
1.18 (m, 1H), 1.76 (b, 1H, D2O exchangeable), 2.13 (m, 2H), 2.32 (b, 1H, D2O 
exchangeable), 2.83 (m, 2H), 2.97 (m, 2H), 3.10 (m, 2H), 3.19 (m, 2H), 3.46 (m, 2H), 
4.08 (m, 1H), 4.20 (m, 1H), 5.10 (b, 1H, D2O exchangeable), 7.05 (d, J=8.1 Hz, 1H), 7.27 
(d, J=8.1 Hz, 1H), 8.74 (m, 2H), 9.18 (m, 2H); 13C-NMR (75 MHz, CD3OD) 
(dihydrochloride salt) δ 2.46, 5.23, 5.80, 23.81, 27.71, 30.97, 34.68, 57.76, 62.11, 69.69, 
70.16, 90.43, 120.88, 121.02, 123.80, 127.02, 127.53, 129.13, 129.71, 132.56, 143.50, 
145.32, 147.69, 149.17, 160.13, 207.27; IR  (cm-1) 748.57, 1241.13, 1270.34, 1724.55, 
1755.48, 3385.42; MS m/z (relative intensity, ion): 446.8 (100%, (M+H)+). 
 
17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(pyridinyl-
3’carboxy)morphinan-6-one (19) 
Following procedure A, nicotinyl chloride (356 mg, 2.0 mmol), naltrexone (300 mg, 0.9 
mmol), DMF (5 mL), and TEA (0.56 mL, 405 mg, 4.0 mmol), are applied.  Product is 
isolated by column chromatography (50:1:0.04 CH2Cl2:MeOH:NH3H2O) and 105 mg 
(24.1% yield) of a white fluffy powder is obtained and converted to hydrochloride salt.   
mp 202°C (decomposed); 1H-NMR (300 MHz, CD3Cl) (free base) δ 0.52 (m, 4H), 1.19 
(m, 1H), 1.71 (m, 2H), 1.86 (m, 2H), 2.26 (m, 2H), 2.34 (m, 2H), 2.65 (m, 2H), 2.78 (m, 
2H), 3.00 (m, 1H), 3.67 (b, 1H, D2O exchangeable), 4.67 (m, 1H), 6.65 (d, J=7.8 Hz, 
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1H), 6.75 (d, J=7.8 Hz, 1H), 7.52 (m, 1H), 8.45 (m,1H), 8.86 (m, 1H), 9.56 (s, 1H); 1H-
NMR (300 MHz, CD3OD) (dihydrochloride salt) δ 0.86 (m, 4H), 1.20 (m, 1H), 1.31 (m, 
2H), 1.74 (b, 1H, D2O exchangeable), 2.03 (b, 1H, D2O exchangeable),  2.13 (m, 2H), 
2.86 (m, 2H), 3.15 (m, 2H),3.33 (m, 2H), 3.41 (m, 2H), 3.59 (m, 1H), 4.08 (m, 1H), 5.39 
(d, J=5.4 Hz, 1H), 5.63 (d, J=5.4 Hz, 1H), 6.75 (b, 1H, D2O exchangeable), 8.28 (m, 1H), 
9.14 (m, 1H), 9.28 (m, 1H), 9.63 (s, 1H); 13C-NMR (75 MHz, CD3OD) (free base) δ 3.30, 
3.46, 9.00, 22.87, 26.56, 30.30, 35.29, 43.47, 50.85, 55.33, 58.86, 89.35, 93.97, 118.21, 
119.76, 123.37, 123.75, 127.42, 137.42, 137.56, 139.31, 143.14, 149.96, 152.17, 163.37, 
207.43; IR (cm-1) 737.60, 1108.04, 1282.53, 1716.37, 2946.50; MS m/z (relative 
intensity, ion): 447.0 (100%, (M+H)+).  
 
17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(benzoylcarboxy)morphinan-6-
one (20) 
Following procedure A, benzoyl chloride (281 mg, 2.0 mmol), naltrexone (300 mg, 0.9 
mmol), DMF (5 mL), and TEA (0.56 mL, 405 mg, 4.0 mmol), are applied.  The next step 
involving dilute H2SO4 and MeOH is unable to remove the benzyl group at the 3-
position.  The reaction mixture is concentrated and stored in freezer overnight.  In order 
to remove the benzyl group at the 3-position, the 200 mg of the di-substituted product is 
dissolved in 20 mL of THF and 5 mL of a saturated K2CO3 aqueous solution that is 
diluted by half.  The mixture is stirred overnight at room temperature.  Next, the mixture 
is separated into a THF layer and water layer.  The water layer is extracted with 40 mL of 
CH2Cl2 (3 times) and the combined organic layers are dried and concentrated.  The 
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product is isolated and purified by column chromatography (200:1:0.04 and 100:1:0.04 
CH2Cl2:MeOH:NH3H2O).  About 40 mg (10.2% yield) of a light yellow powder is 
obtained and converted to hydrochloride salt.  mp 161-165°C; 1H-NMR (300 MHz, 
CDCl3) (free base) δ 0.60 (m, 4H), 1.25 (m, 1H), 1.88 (m, 2H), 2.18 (m, 2H), 2.42 (m, 
2H), 2.62 (m, 2H), 2.68 (m, 2H), 2.98 (m, 2H), 3.05 (m, 1H), 3.27 (m, 1H), 4.72 (b, 1H, 
D2O exchangeable), 6.73 (d, J=8.1 Hz, 1H), 6.96 (d, J=8.1 Hz, 1H), 7.49 (m, 2H), 7.62 
(m, 1H), 8.21 (m, 2H); 1H-NMR (300 MHz, CD3OD) (monohydrochloride salt) δ 0.90 
(m, 4H), 1.30 (m, 1H), 1.79 (b, 1H, D2O exchangeable), 1.95 (m, 2H), 2.10 (m, 2H), 2.47 
(m, 2H), 2.74 (m, 2H), 2.84 (m, 2H), 2.90 (m, 2H), 3.01 (m, 1H), 3.33 (m, 1H), 4.88 (b, 
1H, D2O exchangeable), 7.00 (d, J=9.1 Hz, 1H), 7.14 (d, J=9.1 Hz, 1H), 7.61 (m, 2H), 
7.73 (m, 1H), 8.21 (m, 2H); 13C-NMR (75 MHz, CD3OD) (monohydrochloride salt) δ 
1.56, 4.34, 4.91, 22.87, 26.89, 30.03, 33.76, 56.98, 58.09, 61.64, 62.11, 69.12, 69.35, 
89.12, 93.10, 96.46, 119.74, 122.50, 123.44, 129.31, 129.39, 132.18, 132.66, 133.52, 
147.54, 163.72, 205.92; IR (cm-1) 709.97, 1055.29, 1238.92, 1729.47, 3398.92; MS m/z 
(relative intensity, ion): 447.0 (100%, (M+H)+).   
 
17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(isoquinolinyl-3’-
carboxy)morphinan-6-one (21) 
Following procedure B, 3-isoquinoline carboxylic acid (381 mg, 2.2 mmol), SOCl2 (5 
mL), naltrexone (341 mg, 1.0 mmol), DMF (5 mL), and TEA (0.61 mL, 445 mg, 4.4 
mmol) is applied.  Product is isolated by column chromatography (200:1:0.04 
CH2Cl2:MeOH:NH3H2O) and 117 mg (23.6% yield) of a dark yellow powder is isolated 
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and converted to hydrochloride salt.  mp 201-204°C; 1H-NMR (300 MHz, CDCl3) (free 
base) δ 0.38 (m, 4H), 1.18 (m, 1H), 1.27 (m, 2H), 1.70 (m, 2H), 2.98 (m, 2H),  3.02 (m, 
2H), 3.06 (m, 2H), 3.19 (m, 2H), 3.28 (m, 1H), 3.66 (b, 1H, D2O exchangeable), 4.74 (m, 
1H), 6.78 (d, J=8.1 Hz, 1H), 7.07 (d, J=8.1 Hz, 1H), 7.89 (m, 3H), 8.06 (m, 1H), 8.46 (s, 
1H), 8.73 (s, 1H); 1H-NMR (300 MHz, CD3OD) (monohydrochloride salt) δ 0.84 (m, 
4H), 1.15 (m, 1H), 1.30 (m, 2H), 1.73 (m, 2H), 2.04 (m, 2H), 2.33 (b, 1H, D2O 
exchangeable), 2.78 (m, 2H), 3.33 (m, 2H), 3.46 (m, 2H), 3.59 (m, 1H), 3.64 (b, 1H, D2O 
exchangeable), 4.03 (m, 1H), 7.01 (d, J=8.1 Hz, 1H), 7.21 (d, J=8.1 Hz, 1H), 8.01 (m, 
3H), 8.25 (m, 1H), 8.50 (s, 1H), 8.87 (s, 1H); 13C-NMR (75 MHz, CD3OD) (free base) δ 
3.45, 3.62, 8.97, 22.61, 30.38, 30.79, 43.05, 50.25, 53.68, 58.79, 61.48, 69.63, 90.27, 
119.05, 122.62, 125.01, 126.34, 128.16, 128.34, 129.20, 129.85, 130.19, 130.75, 131.66, 
132.23, 136.64, 138.94, 147.36, 161.70, 207.23; IR (cm-1) 781.33, 1182.05, 1724.96, 
2920.65, 3392.46; MS m/z (relative intensity, ion): 497.4 (100%, (M+H)+). 
 
17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(quinolinyl-2’-
carboxy)morphinan-6-one (22) 
Following the above procedure A, quinaldyl chloride (383 mg, 2.0 mmol), naltrexone 
(300 mg, 0.9 mmol), DMF (5 mL), and TEA (0.56 mL, 405 mg, 4.0 mmol), is applied.  
Product is isolated by column chromatography (50:1:0.04 CH2Cl2:MeOH:NH3H2O) and 
76 mg (17.4% yield) of a white powder is obtained and converted to hydrochloride salt.  
mp 85-88°C; 1H-NMR (300 MHz, CDCl3) (free base) δ 0.18 (m, 4H), 0.59 (m, 1H), 1.29 
(m, 2H), 1.66 (m, 2H), 1.94 (m, 2H), 2.36 (m, 2H),  2.76 (m, 2H), 3.10 (m, 2H), 3.24 (m, 
 
 
 
 106
1H), 3.68 (b, 1H, D2O exchangeable), 4.73 (m, 1H), 6.61 (d, J=4.8 Hz, 1H), 6.62 (d, 
J=4.8 Hz, 1H), 6.76 (m, 1H), 6.79 (m, 1H), 7.29 (m, 1H), 7.52 (d, J=8.1 Hz, 1H), 7.61 (d, 
J=8.1 Hz, 1H), 7.86 (m, 1H); 1H-NMR (300 MHz, CD3OD) (dihydrochloride salt) δ 0.82 
(m, 4H), 1.28 (m, 1H), 1.71 (m, 2H), 1.94 (b, 1H, D2O exchangeable), 2.31 (b, 1H, D2O 
exchangeable), 2.92 (m, 2H), 3.07 (m, 2H), 3.24 (m, 2H), 3.43 (m, 2H), 3.56 (m, 2H), 
4.07 (m, 1H), 4.20 (m, 1H), 5.08 (b, 1H, D2O exchangeable), 7.00 (d, J=8.1 Hz, 1H), 7.26 
(d, J=8.1 Hz, 1H), 7.92 (m, 1H), 8.08 (m, 1H), 8.24 (m, 1H), 8.38 (d, J=8.4 Hz, 1H), 8.50 
(d, J=8.4 Hz, 1H), 8.99 (m, 1H); 13C-NMR (75 MHz, CD3OD) (free base) δ 3.39, 3.62, 
8.96, 22.20, 30.18, 30.94, 35.79, 43.20, 50.60, 58.76, 61.56, 69.90, 90.06, 115.70, 117.66, 
119.50, 121.09, 122.34, 123.52, 127.38, 128.51, 130.28, 131.41, 133.72, 138.64, 140.65, 
143.11, 143.76, 163.00, 209.92; IR (cm-1) 729.62, 1240.22, 1453.50, 1660.32, 1731.42, 
3179.17; MS m/z (relative intensity, ion): 497.1 (100%, (M+H)+). 
 
17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(quinolinyl-3’-
carboxy)morphinan-6-one (23) 
Following procedure B, 3-quinoline carboxylic acid (366 mg, 1.9 mmol), SOCl2 (5 mL), 
naltrexone (307 mg, 0.9 mmol), DMF (5 mL), and TEA (0.51 mL, 364.3 mg, 3.5 mmol), 
is applied.  Product is isolated by column chromatography (60:1:0.04 
CH2Cl2:MeOH:NH3H2O) and 104 mg (21.7% yield) of a light yellow powder is obtained 
and converted to hydrochloride salt.  mp 187°C (decomposed); 1H-NMR (300 MHz, 
CDCl3) (free base) δ 0.38 (m, 4H), 0.93 (m, 1H), 1.80 (m, 2H), 2.05 (m, 2H), 2.28 (m, 
2H), 2.40 (m, 2H), 2.70 (m, 2H), 3.08 (m, 2H), 3.15 (m, 1H), 3.28 (b, 1H, D2O 
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exchangeable), 4.74 (m, 1H), 6.83 (d, J=8.1 Hz, 1H), 7.07 (d, J=8.1 Hz, 1H), 7.67 (m, 
1H), 7.83 (m, 1H), 7.92 (m,  1H), 8.15 m, 1H), 9.07 (s, 1H), 9.61 (s, 1H); 1H-NMR (300 
MHz, CDOH) (dihydrochloride salt) δ 0.86 (m, 4H), 1.20 (m, 1H), 1.86 (b, 1H, D2O 
exchangeable), 2.00 (b, 1H, D2O exchangeable), 2.12 (m, 2H), 2.25 (m, 2H), 2.75 (m, 
2H), 3.02 (m, 2H), 3.15 (m, 2H), 3.33 (m, 2H), 3.49 (m, 1H), 4.25 (m, 1H), 7.08 (d, J=8.1 
Hz, 1H), 4.95 (b, 1H, D2O exchangeable), 7.27 (d, J=8.1 Hz, 1H), 7.93 (m, 1H), 8.32 (m, 
3H), 9.58 (s, 1H), 9.64 (s, 1H); 13C-NMR (75 MHz, CD3OD) (dihydrochloride salt) δ 
1.63, 4.42, 4.97, 13.57, 22.96, 26.93, 30.16, 33.87, 56.97, 61.44, 64.98, 69.37, 89.52, 
120.07, 122.14, 123.29, 123.67, 127.06, 128.19, 128.44, 129.02, 129.70, 132.07, 134.83, 
143.32, 144.14, 146.82, 147.10, 160.69, 206.38; IR (cm-1) 761.94, 1188.51, 1724.96, 
3386.00; MS m/z (relative intensity, ion): 497.1 (100%, (M+H)+). 
 
17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(napthalenyl-2’-
carboxy)morphinan-6-one (24) 
Following procedure A, 2-napthoyl chloride (419.3 mg, 2.2 mmol), naltrexone (341 mg, 
1.0 mmol), DMF (5 mL), and TEA (0.56 mL, 405 mg, 4.4 mmol), is applied.  The next 
step involving dilute H2SO4 and MeOH is unable to remove the naptholene group at the 
3-position.  The reaction mixture is concentrated and stored in freezer overnight.    About 
387 mg of di-substituted product is obtained.  So in order to remove the naptholene 
moiety at the 3-position, 200 mg of the di-substituted product is dissolved in 20 mL of 
THF and 5 mL of a saturated K2CO3 aqueous solution that is diluted by half.  The 
mixture is stirred overnight at room temperature.  Next the mixture is separated into a 
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THF layer and water layer.  The water layer is extracted with 40 mL of CH2Cl2 (3 times) 
and the combined organic layers are dried and concentrated.  The product is isolated by 
column chromatography (200:1:0.04 and 100:1:0.04 CH2Cl2:MeOH:NH3H2O).  About 35 
mg (7.1% yield) of a light brown powder was isolated and converted to hydrochloride 
salt.  mp 137-140°C; 1H-NMR (300 MHz, CDCl3) (free base) δ 0.40 (m, 4H), 1.25 (m, 
1H), 1.93 (m, 2H), 2.75 (m, 2H), 3.04 (m, 2H), 3.38 (m, 2H), 3.45 (m, 2H), 3.70 (m, 2H), 
3.88 (m, 1H), 4.04 (m, 1H), 5.09 (b, 1H, D2O exchangeable), 6.76 (d, J=8.1 Hz, 1H), 7.01 
(d, J=8.1 Hz, 1H), 7.60 (m, 2H), 7.90 (m, 2H), 7.99 (m, 1H), 8.20 (m, 1H), 8.81 (s, 1H); 
1H-NMR (300 MHz, CD3OD) (monohydrochloride salt) δ 0.91 (m, 4H), 1.20 (m, 1H), 
1.34 (m, 2H), 1.86 (b, 1H, D2O exchangeable), 2.16 (m, 2H),  2.53 (m, 2H), 3.53 (m, 
2H), 3.89 (m, 2H), 4.07 (m, 2H), 4.19 (m, 1H), 4.39 (m, 1H), 4.77 (b, 1H, D2O 
exchangeable), 7.02 (d, J=8.1 Hz, 1H), 7.21 (d, J=8.1 Hz, 1H), 7.70 (m, 2H), 8.10 (m, 
4H), 8.97 (s, 1H); 13C-NMR (75 MHz, CD3OD) (monohydrochloride salt) δ 1.50, 4.39, 
4.92, 22.86, 26.90, 33.79, 56.96, 61.65, 69.37, 76.69, 89.18, 93.17, 96.52, 119.17, 119.80, 
122.32, 123.53, 124.37, 126.62, 127.04, 127.36, 127.72, 128.15, 128.70, 131.25, 121.53, 
132.02, 132.78, 135.49, 164.81, 206.04; IR (cm-1) 775.87, 1055.98, 1188.70, 1731.54, 
3386.00; MS m/z (relative intensity, ion): 496.0 (100%, (M+H)+). 
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3. Pharmacological Studies 
3.1 Cell Culture 
 Cells expression the mu-, delta-, and kappa-opioid receptors are grown and 
harvested in order to test the affinities of the naltrexone derivatives.  Chinese hamster 
ovary (CHO) cells that over expressed the mu-opioid receptor (Dr. Dana Selley’s 
laboratories at VCU) and kappa-opioid receptor (Dr. Ping Law at University of 
Minnesota) are grown.  For the delta-opioid receptor, four different cell lines that over 
expressed the delta-opioid receptor are utilized for testing the naltrexone derivatives.  The 
first set of cell lines tested consisted of two CHO cell lines (Dr. Ping Law from the 
University of Minnesota and Dr. Liu-Chen at Temple University) and human embryonic 
kidney 293 (HEK) cells (Dr. Ping Law from the University of Minnesota).  The final cell 
line used is the NG108-15 neurohybrid (Mouse Neuroblastoma x Rat Glioma hybrid) cell 
line because it naturally expresses the delta-opioid receptor (Dr. Dana Selley’s 
laboratories at VCU).   
 
A. Cell Culture Protocol 
Similar protocols are used employed to grow and harvest all of the cell lines used 
for the pharmacology studies.  However, there are some differences in media used for 
each cell line.  Freezebacks of each cell line are obtained from their respective 
laboratories.   
First, the cells are put into a 15 mL falcon tube with complete media and spun 
down at 5000 rpm for 5 minutes.  Complete media consists of FBS (Fetal Bovine Serum, 
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USDA approved, Invitrogen), G418 (Genetecin, Invitrogen), and Penicillin/Streptomycin 
(Invitrogen).  For the NG108-15 and HEK cell lines, 1.5M Hepes (Mediatech) is added 
for a final concentration of 15 mM.  Plain media is just media with no additional 
additives.   
After the cells are spun down, the supernatant is poured off and the pellet is re-
suspended in 10 mL of complete media.  Next, the cells are plated in a tissue dish (100 x 
20 mm, Fischer) with complete media and placed in the incubator set at 37 °C with 5% 
CO2 and 95% humidity.  The cells are left until they were about 80% confluent and then 
passed from 1 to 4 tissue dishes by pouring off the old media and adding 4 mL of Trypsin 
with 0.05% EDTA (Invitrogen).  The cells are put back into the incubator for 3 to 5 
minutes until all the cells were detached from the tissue dish.  Then 4 mL of complete 
media is added to the cells.  Next, 2 mL of the cells in media are added to each tissue 
dish.  Then the cells are placed back into the incubator until they are confluent, this takes 
about 1 to 2 days depending on the cell line.  Two plates are then passed the same way 
from 2 to 8 tissue dishes.  The other 2 tissue dishes are frozen down to create more 
freezebacks. 
After the second passage there are 8 tissue dishes.  When the cells are confluent, 
they are transferred into 8 flasks (175 cm2, Corning) by pouring off the old media and 
adding 4 mL of trypsin.  Then the cells from each tissue dish are added into separate 
flasks.  About 25 mL of complete media is added to each of the flasks and placed back 
into the incubator.  When the cells in the flasks are confluent, they are harvested by 
adding 6 mL of trypsin and put back into incubator for 10 to 15 minutes until all of the 
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cells detached from the flask.  Then 6 mLs of complete media is added and the flasks 
were rinsed about 10 times to break up the cells.  About 9 mL of cells are added into 
falcon tubes and 1 mL of cells was left in the bottom of each flask.  Finally, 25 mL of 
complete media is added to the flasks and put back into incubator.   
The cells in the falcon tubes are spun down at 5000 rpm for 5 minutes.  The 
supernatant is poured off and the cells were re-suspended in 30 mL of 1X PBS (100mL of 
10X PBS liquid concentrated in 900 mL deionized water, VWR) and spun down at 5000 
rpm for 5 minutes.  About 10 mL of TME with no NaCl is added and transferred into a 
polypropylene centrifuge tube.  The cells are spun down again at 50,000 x g for 10 
minutes at 4 °C.  The supernatant is poured off and then 5 mL of TME with no NaCl is 
added and homogenized for 30 seconds.  Next, a Bradford protein determination is run on 
the cells and the cells are divided into 3 mg portion in 2 mL cryovials (Corning) and 
frozen at -80 °C.  The cells are passed until they reach their 20th passage each time 
following the above procedure.   
 
B. Freezeback Protocol 
The freezebacks are created by pouring off the old media and adding 3 mLs of 
trypsin to each plate.  When all of the cells detach from the tissue dish, they are put in a 
falcon tube and spun down at 5000 rpms for 5 minutes.  The supernatant is poured off 
and 2 mL of a freezeback solution was added.  The freezeback solution contains the 
appropriate media for the cells as well as 10% FBS and 10% sterile DMSO (Research 
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Organic Inc.).  The cells are aliquoted into two 1 mL portions in cryovials and put into a -
20 °C freezer for 30 minutes and then moved to the -80 °C freezer for long-term storage. 
  
C. Cell Media Recipe 
 Each of the cell lines used in the pharmacology studies has a different media 
recipe and two types of media were used for the cells.  The CHO cell lines use 
DMEM/F12 (Invitrogen) and the HEK 293 and NG108-15 cell lines use DMEM 
(Invitrogen) media.  The cell media also contains additives including FBS, G418, and 
Penicillin/Streptomycin.   
 A solution of 50 mg/mL of G418 is made by dissolving 5 g of G418 in 100 mL of 
HBSS (Hank’s Balanced Salt Solution, Invitrogen) without Ca2+ and Mg2+ media.  Then 
the pH of the solution is adjusted to 7.4 by the addition of 1N NaOH.  The solution is 
stored in 10 mL portions in the -20 °C freezer till needed.   
 For the NG108-15 and DORHEK cells, a 1.5 M HEPEs solution is added.  This is 
made by making a 1.5 M (35.7 g) HEPEs solution in 100 mL of deionized water.  Then 
the solution is sterile filtered (Stericup Disposable Vacuum Filtration System, 22 μm, 
Millipore, Bedford, MA) under the hood.  The solution is stored in 4 °C refrigerator until 
needed. 
 The FBS is prepared by thawing it overnight in 4 °C refrigerator.  When the FBS 
is completely thawed, it is heat inactivated by placing it in a water bath set at 56 °C for 
30 minutes.  Then the FBS is aliquoted in 100 mL portions into autoclaved bottles.  These 
bottles are then stored in the freezer set at -20 °C until needed. 
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 The media for the DORHEK cells consists of DMEM media with 8% FBS (40 
mL), 1% Penicillin/Streptomycin (5 mL), 1.5 mM Hepes (5 mL), and 0.2 mg/mL G418 
(2 mL).  The media prepared for the DORCHO cells consists of DMEM/F12 with 10% 
FBS (50 mL), 1% Penicillin/Streptomycin (5 mL) and 0.2 mg/mL G418 (2 mL).   
 The media prepared for the KORCHO and MORCHO cells consists of 
DMEM/F12 with 5% FBS (25 mL), 1% Penicillin/Streptomycin (5 mL) and 0.2 mg/mL 
G418 (2 mL).  The DORCHO cells used the same media recipe except it contained 10% 
FBS (50mL) instead of 5% FBS. 
 For the NG108-15 cells the media is prepared similar to the DORHEK cells with 
DMEM media containing 10% FBS (50 mL), 1% Penicillin/Streptomycin (5 mL), 1.5 
mM HEPEs (5 mL), and 0.2 mg/mL G418 (2 mL).  For NG108-15 cells, 2 bottles of a 
50X HAT supplement (final concentration 200 μM Hypoxanthine, 0.8 μM Aminopterin, 
and 32 μM  thymidine, Hybrimax) is added by dissolving the HAT powder in 10 mL of 
deionized water and adding it directly to the media.   
 
3.2 Preparation of Naltrexone and Naltrexamine Derivatives for Radiolabeled 
Binding Assays 
 The 14-O-heterocyclic substituted naltrexone derivatives and the 6-N-heterocyclic 
substituted naltrexamine derivates are prepared for the binding assays by drying them on 
a vacuum pump for at least 2 h.  Then 2 mM stock concentrations of the compounds are 
prepared by first dissolving the compound in a drop of DMSO and using a vortex to mix 
the compound until it was completely dissolved.  Then 1 mL of deionized water is added 
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and mixed again using a vortex.  Finally, the compound is aliquoted into 50 μL portions 
and stored at -20 °C freezer till needed. 
 The above procedure is followed for all of the compounds except compound 17.  
Compound 17 is insoluble in deionized water so it was dissolved in 70% DMSO and 30% 
deionized water to make the 2 mM stock solution.   
  
3.3 Radiolabeled Binding Assays 
A. Saturation or Scatchard Radiolabeled Binding Assay 
 The saturation ligand-binding assay is the main technique used in the 
determination of the availability of the receptors.  In this assay, receptors are incubated 
with increasing concentrations of radiolabeled ligand.  From this assay the Bmax, the 
density or the maximum number of binding sites, and Kd, dissociation constant of the 
radioligand, is determined.101  The saturation assay is conducted for the KORCHO, 
DORCHO and DORHEK cell lines from the University of Minnesota.  Other cell lines 
used includes MORCHO and NG108-15 cell lines from Dr. Selley’s laboratories at 
Virginia Commonwealth University and DORCHO cells from Temple University but the 
saturation assay was not conducted for these cell lines.   
 The buffer that was used in this experiment is TME without NaCl (24.27 g Tris, 
50 mM), 1.16 g MgCl2 (3 mM), 0.312 g EGTA (0.2 mM), 4 L DI water and pH adjusted 
to 7.7 at room temperature).  For this particular assay there will be 8 different 
concentrations of [3H] radioligand ranging from 0.01 nM to 2.0 nM.  All the 
concentrations are done in triplicate with each concentration having non-specific tubes 
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also in triplicate.  The non-specific binding is measured with the addition of same ligand 
as the radioligand but not labeled with tritium.  The total volume in each tube is 500 μL.  
For the total binding it will include the cells, radioligand, and TME without NaCl.  For 
non-specific binding it will include all of the components in total binding as well as the 
addition of cold ligand.   
 Below is a general step-by-step protocol for the saturation binding assay.  
However, some changes are made in certain cases discussed in the discussion and results 
section.   
 
 Preparation of Protein 
  
1. Remove cells from -80 °C freezer and thaw.  Add about 5mL of TME 
buffer with no NaCl into the centrifuge tube for every cell aliquot used. 
 NOTE: Keep all buffers, compounds and cells on ice at all times! 
2. Vortex cells to make sure the cells are completely dissolved in the buffer. 
3. Counterbalance the tubes by weight and centrifuge at 50,000 x g for 10 
minutes at 10 °C. 
4. Pour out the supernatant and keep the pellet.  Re-suspend the pellet in 
about 3 to 4 mLs of the TME buffer with no NaCl for every tube of cells 
used.  
5. Homogenize the cells to make sure they are completely dissolved in the 
buffer.  Keep the cells on ice. 
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6. Conduct the Bradford Protein Determination Assay using BSA (Bovine 
Serum Albumin) as standards using a Beckman DU 640 
Spectrophotometer. 
 
Saturation/Scatchard Assay  
 
1. Propylene culture tubes (12x75 mm) were numbered and placed in racks 
on ice.   
2. First add the appropriate amount of TME with No NaCl to all the culture 
tubes.  Note: Follow spreadsheet made with concentrations and amounts 
of drugs to add to the tubes.  Normally final volume will be 500 μL per 
tube. 
3. For this assay, there are 8 different concentrations of the radioligand used 
ranging from 0.05 to 2 nM.  Each different concentration of radioligand 
will have a Non-specific and binding vials in triplicate, 6 tubes for each 
concentration of radioligand. 
Radioligand used for respective opioid receptor: 
   Mu = [3H] Naloxone 
   Kappa = [3H] NorBNI 
   Delta = [3H] Naltrindol 
4. Make the non-specific with cold drug at 0.1 mM, final concentration will 
be 0.01 mM, and add 50 μL to the non-specific tubes.  You will need 
about 1200 μL of cold drug for each rack. 
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 Non-specific used the following drugs for respective opioid   
receptor: 
   Mu = Naltrexone 
   Kappa = NorBNI 
   Delta = Naltrindol 
5. After selecting concentrations of radioligand to use, make a serial dilution 
to the appropriate concentrations.  Make the drugs 10 times more 
concentrated than final desired concentration.  Add 50 μL to the 
appropriate tubes. 
6. Add 100 μL of cells to each tube.  Vortex the tubes and place into the 
shaking water bath for 90 minutes at 30 °C. 
7. Prepare standards by adding 50 μL of each concentration of radioligand to 
4 mL of scintillation fluid (EconoSafe™ Economical Biodegradable 
Counting Cocktail) in 7 mL scintillation vials.  You will need 3 tubes per 
concentration of radioligand so in total there will be 24 standards.  
8. Fill blue racks with scintillation vials leaving the first and last slots open.  
You will need 3 blue racks for each rack of tubes. 
9. Before the incubation was complete GF/B glass fiber filters (Brandel) 
were placed in the brandel harvester and rinsed with cold 50 mM Tris 
buffer (pH 7.2). 
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10. After 90 minutes, remove rack from water bath and incubation was 
quenched with cold 50 mM Tris buffer and aspirated and rinsed three 
times with cold 50 mM Tris. 
11. Remove filter paper and transfer to scintillation tubes using puncher/filler.  
Fill tubes with 4 mL of scintillation fluid and cap. 
12. Label tubes and shake for 30 to 60 mins.  
13. The bound radioactivity was determined by liquid scintillation 
spectrophotometry (Beckman Coulter LS6500 Scintillation Counter). 
14. Clean Brandel harvester with a little bit of 70% EtOH and rinse with lots 
of deionized water.  
 
B. One-Site Competition Binding Assay 
 The main technique used to characterize the naltrexone derivatives synthesized in 
our laboratoies by a one-site competition binding assay.  In this assay receptors are 
incubated with a constant concentration of radiolabeled ligand that is 0.75 to 1 times the 
Kd value determined in the saturation binding assay and various concentrations of the 
naltrexone derivatives.  From this assay the Ki, the affinity of the unlabeled drug of 
interest for the receptor which uses the Cheng-Prusoff equation, and EC50, the molar 
concentration of the unlabeled drug of interest that produces 50% inhibition of specific 
radioligand binding, is determined.103
 For each naltrexone derivative, the one-site competition binding assay is done for 
the mu-, delta- and kappa-opioid receptors.  For the mu-opioid receptor, the MORCHO 
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cells from Dr. Selley’s laboratories (VCU) are used.  The kappa-opioid receptor data uses 
KORCHO cells from the University of Minnesota.  Both the mu- and kappa-opioid 
receptor data is analyzed using hill plot between 5 and 95 percent inhibition.  The delta-
opioid receptor data uses the DORHEK cells from the University of Minnesota for the 6-
N-heterocyclic substituted naltrexamine derivatives.  This set of data is analyzed using 
nonlinear regression using Prism, a statistical software package.  The 14-O-heterocyclic 
substituted naltrexone derivatives delta-opioid receptor data uses the DORCHO cells 
from Temple University.  This set of data is analyzed by using the hill plot between 5 and 
95 percent inhibition. 
 The buffer uses in this assay is TME buffer without NaCl (24.27 g Tris 50mM), 
1.16 g MgCl2 (3 mM), 0.312 g EGTA (0.2 mM), 4 L DI water and pH adjusted to 7.7 at 
room temperature).  The protein concentration ranges from 9 to 30 μg depending on the 
cells being used.  For this assay, the concentration of the [3H] radioligand will be 0.75 to 
1 times the Kd value determined by the saturation assay.  The non-specific binding is 
measured with the addition of the same ligand as the radioligand but not labeled with 
tritium.  The total volume in each tube is 500 μL.  For this assay, there are 3 types of 
tubes: total binding, non-specific binding, and drugs competition binding.  For the total 
binding, it will include the cells, radioligand, and TME without NaCl.  For non-specific 
binding, it will include all of the components in total binding as well as the addition of 
cold ligand.  For each rack, 2 different drugs can be tested with 7 different 
concentrations.  These tubes will include radioligand, cells, drug of interest and TME 
with no NaCl.  All of these tubes are done in triplicate.  A serial dilution of the drugs of 
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interest is made 10 times more concentrated than the final concentrations that ranged 
from 0.001 nM to 1000 nM.  The concentration ranges can be narrowed down to get a 
more accurate Ki value.   
 The basic protocol is very similar to the saturation assay.  The general step-by-
step protocol for the competition binding assay can be seen below and some changes are 
made in certain cases discussed in the discussion and results section.   
 
Preparation of Protein 
  
1. Remove cells from -80°C freezer and thaw.  Add about 5mL of TME 
buffer with no NaCl into the centrifuge tube for every cell aliquot used. 
 NOTE: Keep all buffers, compounds and cells on ice at all times! 
2. Vortex cells to make sure the cells are completely dissolved in the buffer. 
3. Counterbalance the tubes by weight and centrifuge at 50,000 x g for 10 
minutes at 10°C. 
4. Pour out the supernatant and keep the pellet.  Re-suspend the pellet in 
about 3 to 4 mLs of the TME buffer with no NaCl for every tube of cells 
used.  
5. Homogenize the cells to make sure they are completely dissolved in the 
buffer.  Keep the cells on ice. 
6. Conduct the Bradford Protein Determination Assay using BSA (Bovine 
Serum Albumin) as standards using a Beckman DU 640 
Spectrophotometer. 
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One-site Competition Binding Assay  
 
1. Propylene culture tubes (12x75 mm) were numbered and placed in racks 
on ice.   
2. First, add the appropriate amount of TME with No NaCl to all the culture 
tubes.  Note: Follow spreadsheet made with concentrations and amounts 
of drugs to add to the tubes.  Normally final volume will be 500 μL per 
tube. 
3. Make the cold drug 10 x more concentrated than the final desired 
concentration in TME with no NaCl.  So, the concentration should be 100 
μM with a final concentration 10 μM.  Add 50 μL to the appropriate tubes 
in triplicate.  This is your non-specific. 
 Non-specific used the following drugs for respective opioid   
receptor: 
   Mu = Naltrexone 
   Kappa = NorBNI 
   Delta = Naltrindol 
4. Make the dilutions of your drugs in TME with no NaCl and add 50 μL of 
drug to appropriate tubes.  The drugs should be made 10 times more 
concentrated than the desired concentration.  Also, in the beginning you 
should test a wide range before narrowing it down.  Note: You can do 2 
drugs per rack in triplicate. 
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5. Make the stock solution of the radioligand 10 times more concentrated 
than desired concentration in TME with no NaCl.  Add 50 μL to all the 
tubes.  Note: The concentration of radioligand is normally 0.75 to 1 
times of its Kd. 
  Radioligand used for respective opioid receptor: 
   Mu = [3H] Naloxone 
   Kappa = [3H] NorBNI 
   Delta = [3H] Naltrindol 
6. Add 100 μL of cells to each tube.  Vortex the tubes and place into the 
shaking water bath for 120 minutes at 30 °C. 
7. Prepare standards by adding 50 μL of radioligand to 4 mL of scintillation 
fluid (EconoSafe™ Economical Biodegradable Counting Cocktail) in 7 
mL scintillation vials in triplicate.  Cap and label the standards. 
8. Fill blue racks with scintillation vials leaving the first and last slots open.  
You will need 3 blue racks for each rack of tubes. 
9. Before the incubation was complete, GF/B glass fiber filters (Brandel) 
were placed in the brandel harvester and rinsed with cold 50 mM Tris 
buffer (pH 7.2). 
10. After 120 minutes, remove rack from water bath and incubation was 
quenched with cold 50 mM Tris buffer and aspirated and rinsed three 
times with cold 50 mM Tris. 
 
 
 
 123
11. Remove filter paper and transfer to scintillation tubes using puncher/filler.  
Fill tubes with 4 mL of scintillation fluid and cap. 
12. Label tubes and shake for 30 to 60 minutes.  
13. The bound radioactivity was determined by liquid scintillation 
spectrophotometry (Beckman Coulter LS6500 Scintillation Counter). 
14. Clean Brandel harvester with a little bit of 70% EtOH and rinse with lots 
of deionized water.  
 
C. Functional [35S] GTPγS Assay – Agonism of Compounds Compared with 
DAMGO 
The [35S]GTPγS functional binding assay measures the level of G-protein 
activation following the binding of an agonist to a G-protein coupled receptor.  This 
assay is useful to measure the functional activity of a ligand for a certain receptor 
including potency, efficacy and antagonistic affinity.  Since this assay analyzes the 
earliest receptor-mediated events, the measures obtained from the agonist are not subject 
to amplification or other modulation that may occur further downstream from the 
receptor.  From the functional [35S] GTPγS binding assay we can determine the Emax, 
the maximum effect of the drug or the efficacy, and the EC50, the molar concentration 
that produces 50% of the maximum possible effective response normally for an agonist 
or the potency.  DAMGO, a full mu-opioid receptor agonist, is used to compare with our 
drugs.  For this assay, we use TME with NaCl because Na+ decreases spontaneous 
receptor activity. 
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 In the assay, [35S]GTPγS replaces the endogenous GTP that binds to the Gα 
subunit when the receptor is activated (Figure 31).  Since the γ-thiophosphate bond is 
poorly hydrolyzed by GTPase, the G-protein is prevented from reforming the 
heterotrimer (Figure 32).115  Therefore, the [35S]GTPγS labeled Gα subunits accumulate 
and can be measured by counting the amount of [35S]-label incorporated.  The Gα subunit 
remains associated with the membrane by filtering the preparation through filters and 
counting the radioactivity retained on the filter.101 
 
 
 
Figure 31. Guanine-nucleotide exchange in G-protein coupled receptor signaling cycle.  
(A) Low-affinity state of receptor where G-protein is uncoupled from the receptor.  The 
agonist binds and induces receptor conformational change.  (B) High-affinity state of 
receptor where the receptor is coupled to the G-protein, this is also known as the ternary 
complex.  The ternary complex consists of an agonist, receptor and G-protein.  Activation 
of receptor will release bound GDP and bind GTP.  (C) The Gα subunit of the G-protein 
dissociates from the complex and interacts with downstream second messenger elements.  
The Gα subunit is turned off when the bound GTP undergoes a hydrolysis reaction to 
reform GDP and the receptor returns to inactive state.108
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Figure 32. Chemical Structure of [35S]GTPγS. 
   
For each naltrexone derivative, a functional assay is done for the mu-opioid 
receptors.  For the mu-opioid receptor, the MORCHO cells from Dr. Selley’s laboratories 
(VCU) are used.   
 The buffer that is used in this assay is TME buffer with NaCl (24.27 g Tris 50 
mM), 1.16 g MgCl2 (3 mM), 0.312 g EGTA (0.2 mM), 28.38 g NaCl (100 mM), 4L DI 
water and pH adjusted to 7.7 at room temperature.  The protein concentration ranges from 
9 to 10 μg depending of MORCHO cells being used.  For this assay, [35S]GTPγS 
radioligand is used and the concentration of the radioligand is made to equal 125,000 
DPMs (disintegrations per minute).  The non-specific binding is measured with the 
addition of cold GTPγS or not labeled with [35S].  The total volume in each tube is 500 
μL.  For this assay, there are 4 different conditions: basal, non-specific binding, DAMGO 
binding and drug binding.  For the basal, it will include the cells, GDP, radioligand, and 
TME with NaCl.  For non-specific binding, it will include all of the components in basal 
binding as well as the addition of cold GTPγS.  For DAMGO, the tubes include 
DAMGO, GDP, cells and TME with NaCl.  For each rack, 2 different drugs can be tested 
one with 6 different concentrations and one with 7 different concentrations.  These tubes 
 
 
 
 126
will include radioligand, cells, GDP, drug of interest and TME with NaCl.  All of these 
tubes are done in triplicate.  A serial dilution of the drugs of interest was made 10 times 
more concentrated than the final concentrations that ranged from 0.001 nM to 10000 nM.  
After an idea of the value of the EC50 has been determined, it is possible to narrow the 
concentration ranges to be around that value.   
 The general step-by-step protocol for the functional binding assay below and 
some changes are made in certain cases discussed in the discussion and results section.    
 
Preparation of Protein 
  
1. Remove cells from -80 °C freezer and thaw.  Add about 5mL of TME 
buffer with NaCl into the centrifuge tube for every cell aliquot used. 
 NOTE: Keep all buffers, compounds and cells on ice at all times! 
2. Vortex cells to make sure the cells are completely dissolved in the 
buffer. 
3. Counterbalance the tubes by weight and centrifuge at 50,000 x g for 10 
minutes at 10 °C. 
4. Pour out the supernatant and keep the pellet.  Re-suspend the pellet in 
about 3 to 4 mLs of the TME buffer with NaCl for every tube of cells 
used.  
5. Homogenize the cells to make sure they are completely dissolved in the 
buffer.  Keep the cells on ice. 
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6. Conduct the Bradford Protein Determination Assay using BSA (Bovine 
Serum Albumin) as standards using a Beckman DU 640 
Spectrophotometer. 
 
GTPγS Functional Binding Assay  
 
1. Propylene culture tubes (12x75 mm) were numbered and placed in racks 
on ice.   
2. First, add the appropriate amount of TME with NaCl to all the culture 
tubes.  Note: Follow spreadsheet made with concentrations and amounts 
of drugs to add to the tubes.  Normally final volume will be 500 μL per 
tube. 
3. Make the cold GTPγS to 10 μM concentration (final concentration will be 
1 μM) according to work up table in TME with NaCl and add 50 μL to the 
appropriate tubes in triplicate.  Cold GTPγS is used to measure your non-
specific. 
4. Make the dilutions of your drugs and add 50 μL of drug to appropriate 
tubes.  Note: The drugs should be 10 times more concentrated then the 
final concentration.  Also, in the beginning you should test a wide range 
before narrowing it down.  Note: You can make 2 drug in triplicate for 
each rack. 
5. Make a 100 μM solution of GDP (final concentration will be 10 μM) in 
TME with NaCl and add 50 μL in to all the tubes. 
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6. Make the stock solution of the [35S] GTPγS radioligand with TME with 
NaCl.  Add 50 μL to all of the tubes.  Note: For 1 aliquot of [35S]GTPγS, 
about 5 μL, you will need around 5 mL of TME with NaCl.  Basically, 
you need to make your standards to be around 125,000 DPM so check 
by adding 50 μL to 4 mL of scintillation fluid (EconoSafe™ 
Economical Biodegradable Counting Cocktail) in 7 mL scintillation 
vials in triplicate and check with scintillation counter. 
7. Add 100 μL of cells to each tube.  Vortex the tubes and place into the 
shaking water bath for 90 minutes at 30 °C. 
8. Fill blue racks with scintillation vials leaving the first and last slot open.  
You will need 3 blue racks for each rack of tubes. 
9. Before the incubation was complete GF/B glass fiber filters, (Brandel) 
were placed in the brandel harvester and rinsed with cold 50 mM Tris 
buffer (pH 7.2). 
10. After 90 minutes, remove rack from water bath and incubation was 
quenched with cold 50 mM Tris buffer and aspirated and rinsed three 
times with cold 50 mM Tris. 
11. Remove the rack from the water bath and aspirate the tubes and rinse 3 
times with cold tris. 
12. Remove filter paper and transfer to scintillation tubes using puncher/filler.  
Fill tubes with 4 mL of scintillation fluid and cap. 
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13. Label tubes and place in counter with a 9 hour delay use program 10 and 
place a rack with any 3 vials from any previous assay.  Note: Each vial 
will be counted for 3 hours. 
14. The bound radioactivity was determined by liquid scintillation 
spectrophotometry (Beckman Coulter LS6500 Scintillation Counter). 
15. Clean Brandel harvester with a little bit of 70% EtOH and rinse with lots 
of deionized water.  
 
D. Functional [35S]GTPγS Assay – Competition of Naltrexamine Derivatives 
with DAMGO 
 Next, the step is to determine whether the 6-N-heterocyclic substituted 
naltrexamine derivatives were antagonists by conducting a functional [35S] GTPγS assay 
where the drug of interest is competing against DAMGO, a full mu-opioid agonist.  From 
this functional [35S] GTPγS binding assay we can determine the Emax, the maximum 
effect of the drug or the efficacy, and the EC50, the molar concentration that produces 
50% of the maximum possible effective response normally for an agonist or the 
potency.107  DAMGO, a full mu-opioid agonist, is used to compare with our drugs.  For 
this assay, TME with NaCl is used because Na+ decreases agonist binding and will barely 
affect antagonist binding. 
 For each naltrexone derivative, a functional assay is done for the mu-opioid 
receptors.  For the mu-opioid receptor, the MORCHO cells from Dr. Selley’s laboratories 
(VCU) is used.   
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 The buffer that is used in this assay is TME buffer with NaCl (24.27 g Tris 
50mM), 1.16 g MgCl2 (3 mM), 0.312 g EGTA (0.2 mM), 28.38 g NaCl (100 mM), 4L DI 
water and pH adjusted to 7.7 at room temperature).  The protein concentration ranges 
from 9 to 10 μg depending of MOR CHO cells being used.  For this assay, [35S]GTPγS 
radioligand is used and the concentration of the radioligand is made to equal 125,000 
DPMs (disintegrations per minute).  The non-specific binding is measured with the 
addition of cold GTPγS or not labeled with [35S].  The total volume in each tube is 500 
μL.  For this assay, there are 4 types of tubes: basal, non-specific binding, DAMGO 
binding and drug binding.  The basal includes the cells, GDP, radioligand, and TME with 
NaCl.  For non-specific binding, it will include all of the components in Basel binding as 
well as the addition of cold GTPγS.  For the set of DAMGO, tubes include DAMGO, 
GDP, cells and TME with NaCl.  There are 7 different concentrations of DAMGO used 
ranging from 0.001 to 10 nM.  The first set of tubes is just DAMGO and then the last set 
of 7 tubes is DAMGO at different concentrations with a single concentration of the drug 
of interest.  Normally the concentration of the drug of interest is about 10 times its Ki 
value.   For each rack, only 1 different drug can be tested.  These tubes will include 
radioligand, cells, GDP, DAMGO, the drug of interest and TME with NaCl.  All of these 
tubes are done in triplicate.   
 For these assays, the Ke value is determined for the drug of interest by comparing 
the right shift in the curve produced by the addition of the drug of interest to DAMGO. 
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 The general step-by-step protocol for the functional competition binding assay of 
DAMGO and drug of interest can be seen below.  Some changes are made in certain 
cases discussed in the discussion and results section.   
Preparation of Protein 
  
1. Remove cells from -80 °C freezer and thaw.  Add about 5mL of TME 
buffer with NaCl into the centrifuge tube for every cell aliquot used. 
 NOTE: Keep all buffers, compounds and cells on ice at all times! 
2. Vortex cells to make sure the cells are completely dissolved in the 
buffer. 
3. Counterbalance the tubes by weight and centrifuge at 50,000 x g for 10 
minutes at 10 °C. 
4. Pour out the supernatant and keep the pellet.  Re-suspend the pellet in 
about 3 to 4 mLs of the TME buffer with NaCl for every tube of cells 
used.  
5. Homogenize the cells to make sure they are completely dissolved in the 
buffer.  Keep the cells on ice. 
6. Conduct the Bradford Protein Determination Assay using BSA (Bovine 
Serum Albumin) as standards using a Beckman DU 640 
Spectrophotometer. 
 
GTPγS Functional Binding Assay  
 
1. Propylene culture tubes (12x75 mm) were numbered and placed in racks 
on ice.   
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2. First, add the appropriate amount of TME with NaCl to all the culture 
tubes.  Note: Follow spreadsheet made with concentrations and amounts 
of drugs to add to the tubes.  Normally final volume will be 500 μL per 
tube. 
3. Make the cold GTPγS to 10 μM concentration (final concentration will be 
1 μM) according to work up table in TME with NaCl and add 50 μL to the 
appropriate tubes in triplicate.  Cold GTPγS is used to measure your non-
specific. 
4. Make the dilutions of your drugs and add 50 μL of drug to appropriate 
tubes.  Note: The drugs should be 10x more concentrated then the final 
concentration.  Also in the beginning you should test a wide range before 
narrowing it down.  Note: You can make 2 drug in triplicate for each 
rack. 
5. Make a 100 μM solution of GDP (final concentration will be 10 μM) in 
TME with NaCl and add 50 μL in to all the tubes. 
6. Make the stock solution of the [35S] GTPγS radioligand with TME with 
NaCl.  Add 50 μL to all of the tubes.  Note: For 1 aliquot of [35S]GTPγS, 
about 5 μL, you will need around 5 mL of TME with NaCl.  Basically, 
you need to make your standards to be around 125,000 DPM so check 
by adding 50 μL to 4 mL of scintillation fluid (EconoSafe™ 
Economical Biodegradable Counting Cocktail) in 7 mL scintillation 
vials in triplicate and check with scintillation counter. 
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7. Add 100 μL of cells to each tube.  Vortex the tubes and place into the 
shaking water bath for 90 minutes at 30 °C. 
8. Fill blue racks with scintillation vials leaving the first and last slot open.  
You will need 3 blue racks for each rack of tubes. 
9. Before the incubation was complete GF/B glass fiber filters (Brandel) 
were placed in the brandel harvester and rinsed with cold 50 mM Tris 
buffer (pH 7.2). 
10. After 90 minutes, remove rack from water bath and incubation was 
quenched with cold 50 mM Tris buffer and aspirated and rinsed three 
times with cold 50 mM Tris. 
11. Remove the rack from the water bath and aspirate the tubes and rinse 3 
times with cold tris. 
12. Remove filter paper and transfer to scintillation tubes using puncher/filler.  
Fill tubes with 4 mL of scintillation fluid and cap. 
13. Label tubes and place in counter with a 9 h delay use program 10 and 
place a rack with any 3 vials from any previous assay.  Note: Each vial 
will be counted for 3 hours. 
14. The bound radioactivity was determined by liquid scintillation 
spectrophotometry (Beckman Coulter LS6500 Scintillation Counter). 
15. Clean Brandel harvester with a little bit of 70% EtOH and rinse with lots 
of deionized water.  
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4. Data Analysis of Pharmacological Studies 
 The competition binding assays are used to determine the affinity of these 14-O-
heterocyclic substituted naltrexone derivatives and 6-N-heterocyclic substituted 
naltrexamine derivatives for all three opioid receptors.  From the assay, the IC50 values 
are determined, and using the Cheng-Prusoff equation, the IC50 values can be converted 
into Ki values (Figure 33).103 
 
Ki = IC501 + (D/KD)
_____________________
 
Figure 33. Cheng-Prusoff equation. This is the equation to convert the IC50 of a ligand to 
the Ki or the concentration required to produce 50% inhibition of the competing 
radioligand.  The D represents the concentration of radioligand and the Kd is the 
dissociation constant of the radioligand binding to the receptor.103
  
 A graphical representation, competition binding curve, is created consisting of the 
log concentration of the naltrexone derivative versus the percent of radioligand bound for 
each concentration of naltrexone derivative.  Only the linear portion of the curve, where 5 
to 95% of the radioligand is bound, is considered in determining the IC50 value. IC50 is 
determined where the concentration of the competitive ligand produces 50% inhibition of 
the competing radioligand (Figure 34).116
 The standard error of the mean was determined for each compound and the ratio 
between delta- to mu-opioid receptors and kappa- to mu-opioid receptors was 
determined. 
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Figure 34. Competition binding curve.  Binding of a single concentration of labeled 
ligand in the presence of various concentrations of unlabeled ligand.  The IC50 is 
determined where there is 50% radioligand bound to receptor.117 
 
 
 In order to characterize the agonistic activity of these naltrexone derivatives, a 
functional binding assay was conducted, and the 14-O-heterocyclic substituted naltrexone 
derivatives and 6-N-heterocyclic substituted naltrexamine derivatives Emax values are 
compared to the Emax value for DAMGO.  Competition binding curves are constructed 
from the data where the log concentration of the unlabeled drug is on the x-axis and the 
percent stimulation of the receptor by the binding of [35S]GTPγS is on the y-axis.  From 
the curves, the potency, or EC50, and the intrinsic efficacy, or Emax, are determined.  The 
EC50 is the molar concentration of an agonist to produce 50% of the maximal possible 
effect and the Emax is the maximum effect of the agonist.106  DAMGO has an Emax 
value of 366% stimulation of receptor and represents 100% agonist activity.  All of the 
naltrexone derivatives are compared to DAMGO’s Emax value in order to determine 
whether these compounds are agonists, partial agonists or antagonist profiles.  Since the 
measurement is taken at the first step of activation where GTP binds, amplification is not 
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a factor and provided the best source of information about ligand-induced events at the 
receptor.118
Stimulation of [35S]GTPγS through binding of an agonist produces a sigmoidal 
concentration effect curve (Figure 34).  Therefore, the effects of competitive antagonists 
can be measured using a similar [35S]GTPγS assay.  The shifts in the agonist 
concentration-effect curve for the [35S]GTPγS binding in the presence of a single-
concentration of antagonist can be measured.  A dissociation constant, Ke, for the 
antagonist is determined from the right shift in the agonist concentration-effect curve 
(Figure 35).  From the Ke, the reciprocal can be taken and defined as the affinity of the 
antagonist such that when the degree of shift of the agonist dose-response curve is 2 fold, 
the –log10Ke=pA2 where Ke is in molar concentration.  The pA2 value is the apparent 
affinity that is the negative log of the molar concentration of antagonist that makes it 
necessary to double the concentration of the agonist needed to elicit the original 
submaximal response obtained in the absence of antagonist.  This analysis assumes the 
antagonist is competitive and not dependent on how the antagonist acts.106,107 
Ke =  [Antagonist]
(Dose Ratio-1)
Dose Ratio = [EC50 DAMGO + Antagonist]
          [EC50 DAMGO]
__________________________________
________________
 
 
Figure 34. Determination of the dose ratio and dissociation constant (Ke).   The dose 
ratio is determined from the EC50 of DAMGO with a single concentration of antagonist 
present over the EC50 of DAMGO by itself.  The Ke is determined from the concentration 
of the antagonist divided by the dose ratio minus 1.107 
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Figure 35. [35S]GTPγS functional competition binding curve.  Concntration curve of the 
binding of a full agonist at varying concentrations and the addition of a single 
concentration of antagonist to produce a right shift in the curve.  A dose ratio can be 
calculated to determine the dissociation constant, Ke, for the antagonist.117 
 
5. Molecular Modeling Studies 
5.1 Homology Model of the Mu-Opioid Receptor 
 A homology model of the mu-opioid receptor was built based on the X-ray crystal 
structure of bovine rhodopsin (1U19) with a resolution of 2.2 Å.109  A primary sequence 
alignment was conducted using Clustal X.  Rhodopsin sequence was aligned with the 
human mu-opioid receptor sequence as well as human delta- and kappa-opioid receptors 
for a more accurate alignment.  The helices were identified based the alignment in 
reference to the conserved residues in all GPCRs.119  The bovine rhodopsin crystal 
structure was downloaded into Sybyl 7.1 from the Protein Data Bank.  All seven helices 
of bovine rhodopsin were mutated and the N terminus and C terminus of mu-opioid 
receptor was cleaved off before Ile68 and after Pro355 respectively.  Loop searches were 
conducted for EL (extracellular loops) 1, 2 and 3, IL (intracellular loop) 3 and the 
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beginning of TM (transmembrane) 2.  It was very important to maintain the same 
backbone orientation of rhodopsin in the mu-opioid receptor homology model’s EL2 and 
the TM helices part since they were involved in the binding pocket of most GPCRs.  
Once the mu-opioid receptor model was generated, SCWRL (Side Chain Placement with 
Rotamer Library) was used to minimize sidechain-backbone and sidechain-sidechain 
clashes.  Since SCWRL broke the disulfide bond between cysteine amino acid residues 
130 of TM3 and 180 of EL2, they were rejoined manually.  Also, hydrogens are added 
and lone pairs of electrons were deleted.  Then the receptor model conformation is 
minimized and the backbone validation was conducted using ProTable.  ProTable 
program was used to check the geometry and stereochemistry of the backbone and 
sidechains of the receptor.   
 
5.2 Binding Pocket Modification of the Mu-Opioid Receptor and Ligand 
Docking Studies 
  Compound 22 was manually docked into the binding pocket of MOR because it 
has a very high binding affinity to MOR (Ki = 1.439 nM) among all of the 14-O-
heterocyclic substituted naltrexone derivatives. Site-directed mutagenesis data was used 
in order to position this compound within the mu-opioid receptor and to help characterize 
the binding pocket.106,116   First, the protonated nitrogen near the cyclopropylmethyl 
group may form hydrogen bond or have ionic interaction with carboxyl group of Asp149 
located on TM3 of MOR.  It was reported that the Tyr150 residue locating also on TM3 
might interact with the phenolic moiety at the third position of the naltrexone derivative.  
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The aromatic moiety Phe223 located on EL2 may also interact through hydrophobic 
interactions with the phenolic moiety at the third position of the naltrexone derivative.  It 
has been reported that Trp320 located on TM7 has a hydrophobic interaction with the 
piperidinyl and cyclohexanonly rings in the naltrexone skeleton.  Finally, Tyr328 also 
located on TM3 was shown to be an important recognition site for naltrexone through 
mutation to a phenyalanine which shows decreased binding affinity to naltrexone.  
Tyr328 might interact with the protonated amine and the C14 hydroxyl group of the 
naltrexone skeleton.  
 The compound was then merged into the receptor and locked into place.  Another 
round of minimization is conducted to get the receptor into the lowest energy 
confirmation possible.  The receptor is minimized for 100,000 iterations using Gasteiger-
Hückel charges and a dielectric constant of 4.0.   
 Dynamic simulations were also run for 100,000 iterations, snapshots were taken 
every 25 fs, with Gasteiger-Hückel charges and a dielectric constant of 4.0.  In addition to 
these normal settings for a molecular dynamics run of a membrane protein, an aggregate 
was setup around the ligand in order to keep the receptor from falling apart.  Therefore, a 
radius of 8.0 Å is setup around the ligand and this area is the only part of the receptor-
ligand complex that underwent dynamics simulation.  When the simulation was 
complete, the last 2000 fs of the receptor was combined and minimized using the 
previous settings.  The ligand was removed from the receptor and the 14-O-heterocyclic 
substituted naltrexone derivatives underwent docking studies. 
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 All of the 14-O-heterocyclic substituted naltrexone derivatives were drawn into 
Sybyl 7.1 with a protonated amine and their conformations are minimized.  GOLD 
(Genetic Optimization for Ligand Docking) 3.1 was used to perform docking studies for 
all of the ligands.  The default settings were used and the active site radius was set to 15 
Å measured from O1278, C1277, and O1279 from Asp149.  Next, the distance 
constraints of 2 to 4 Å were set between O1278 to the positively charged nitrogen of the 
naltrexone derivatives.  The best docking solutions of all the ligands were assessed using 
Sybyl 7.1. 
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